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ABSTRACT OF THE DISSERTATION 
EXPRESSION AND FUNCTION OF snoRNAS IN ACUTE MYELOID LEUKEMIA 
 by 
Wayne Alsworth Warner 
Doctor of Philosophy in Biology and Biomedical Sciences  
(Molecular Cell Biology) 
Washington University in St. Louis, 




Small nucleolar RNAs (snoRNAs) are non-coding RNAs that contribute to ribosome 
biogenesis and RNA splicing by modifying ribosomal RNA and spliceosome RNAs, 
respectively.  These modifications are critical for a variety of cellular processes, including 
ribosomal biogenesis and splicing of RNAs.  Recent studies have suggested an expanded 
role for snoRNAs beyond ribosomal biogenesis and splicing, including, regulation of 
chromatin structure, metabolism, and neoplastic transformation.  The contribution of 
snoRNAs to the regulation of normal and malignant hematopoiesis is largely unknown.  
The lack of a method to accurately and comprehensively assess snoRNA expression has 
limited research in this area.   In particular, array-based methods only interrogate a subset 
of snoRNAs and cannot distinguish between mature and precursor snoRNAs.   To better 
characterize the role of snoRNAs in the regulation of hematopoiesis, we therefore 
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developed a next-generation sequencing technique and bioinformatic approaches to 
quantify snoRNAs accurately.    
We used our snoRNA sequencing pipeline to characterize snoRNA expression in 
acute myeloid leukemia (AML).   We show that snoRNAs are regulated in a lineage- and 
development-specific fashion in normal hematopoiesis.   Surprisingly, RNA splicing did 
not appear to be a major determinant of expression for most snoRNAs.   Expression of 
most snoRNAs in AML cells was similar to that observed in normal CD34+ cells.   In 
contrast to a prior study, no increased in C/D box snoRNAs was observed in core binding 
factor AML.   On the other hand, certain snoRNAs appear to be dysregulated in specific 
genetic subtypes of AML.   In particular, snoRNAs in the imprinted DLK1-DIO3 locus are 
markedly overexpressed in acute promyelocytic leukemia.   We also observed reduced 
expression of SNORA21 in several genetic subtypes of AML, most notably AML carrying 
spliceosome gene mutations.   
SNORA21 mediates pseudouridylation of key nucleotides in the peptidyl transfer 
center region of rRNA.  To better understand the impact of reduced SNORA21 expression 
in AML, we generated SNORA21 null K562 cells using CRISPR gene editing.  Loss of 
SNORA21 in K562 cells is associated with impaired ribosome biogenesis and reduced 
global translation.  However, ribosome profiling/RNASeq suggests that only a few genes 
show significant changes in translational efficiency.  Loss of SNORA21 in K562 cells 
results in reduced cellular proliferation due to an increase in non-apoptotic cell death.  
Electron microscopy and mitochondrial assays of SNORA21-/- K562 cells suggest that 
reduced mitochondrial function may contribute to the increase in cell death.   
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Collectively these data provide compelling evidence for snoRNA involvement in 
leukemogenesis and highlights the importance of ribosomal biogenesis as a basis to 
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Discovery of snoRNAs 
The term snoRNA was first used in 1981, more than a decade after the first small nuclear 
RNAs were detected and the first nucleolar species was identified1.  The U3 (SNORD3) 
species was the first to be described in detail after detection during fractionation of small 
RNA prepared from rat cell nuclei by gel electrophoresis2.  It is ubiquitous among 
eukaryotes and is the most abundant of all snoRNAs with a key function in the 
endonucleolytic cleavage of precursor rRNA3. Sequence analysis of SNORD3 revealed 
several conserved ‘box’ sequences (A-D) where A and B box regions are upstream of the 
C and D boxes4,5.  Box C/D elements were determined to be present in other small nuclear 
RNAs discovered some years later (1989) and this common feature formed the genesis 
of the box C/D nomenclature subsequently used to define one of the two large families of 
snoRNAs6. 
In 1983, gel electrophoresis fractionation strategies were used to describe the 
population of small nuclear yeast RNAs leading to the discovery of splicing snRNAs and 
other snoRNAs7,8.  In 1996, the other large family of snoRNAs (box H/ACA) was identified 
in yeast from comparative sequencing of nuclear small RNAs7,9-11.  Over the years, yeast, 
human, mouse and Xenopus cell models were used for expression, discovery, 
biosynthesis and function studies.  snoRNAs have been identified in a variety of other 
metazoan organisms (e.g., mouse, rat, Xenopus and plants), and in protists. 
 
snoRNA structure and classification 
In humans, snoRNAs typically accumulate in the nucleolus, vary in size from 60-300nt 
(median 133nt) and are mostly encoded in the introns of translation associated host 
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genes.  During splicing, snoRNAs are stabilized by formation of a small nucleolar RNA-
protein complexes (snoRNPs).  There are two main types of snoRNAs, box H/ACA 
(SNORA) and box C/D snoRNA (SNORD) which differ by the protein complex, secondary 
structure, conserved elements, function and size.  A third class, Cajal body-specific RNAs 
(scaRNAs), which accumulate in the Cajal bodies are involved in the post-transcriptional 
modification of snRNAs and are usually characterized by composite H/ACA and C/D 
boxes12,13. 
 
H/ACA box snoRNAs 
H/ACA box snoRNAs (SNORAs) contain 2 hairpins forming the evolutionarily conserved 
hairpin-hinge-hairpin-tail configuration that characterizes its secondary structure14-16. 
They have two short consensus sequence motifs critical for stability and accumulation, 
box H (ANANNA) located in the hinge region near the 5’ end and the box ACA motif 
containing the triplet ACA exactly 3 nucleotides upstream of the 3′ end, in the tail region 
(Figure 1A)7,17.  The H/ACA boxes influence the synthesis and function of both the 
snoRNAs and corresponding snoRNPs.  Of importance, the H/ACA boxes are involved in 
providing structural stability and biological function, defining the ends of the mature 
snoRNA (ACA), localization to the nucleolus and Cajal bodies, and pseudouridylation7,9-
11,18-23.    
Each hairpin contains an internal loop, the pseudouridylation pocket characterized 
by short bipartite recognition sequences (3-10 nts) complementary to the substrate pre-
RNA containing the target uridine moiety that will be isomerized to pseudouridine (Ψ) 
(Figure 1A).  The Ψ guide snoRNAs are specifically located in the bulge region of one or 
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both folded domains/internal loops9.  For targeted specific site selection to occur there 
must be base pairing of the two guide sequences with substrate nucleotides that flank the 
uridine to be isomerized, and a distance of 14-16 nts between the target uridine and the 
corresponding H or ACA box element9,23.   Interestingly, a single pseudouridine guide 
snoRNA can use one or both of the guide domains to target modification.  This suggests 
that the actual modification capacity might be larger than currently known suggesting that 
SNORAs might have additional functions.  
Complexing on the SNORA scaffold are four core proteins: Gar1, Nhp2 and Nop10 
and the pseudouridine synthase, dyskerin (DKC1)30,31.  Gar1 and Nhp2p are known to 
interact directly with H/ACA snoRNAs.   Interestingly, Nhp2 is 38% identical and 61% 
similar at the amino acid level to the C/D snoRNP protein Snu13p/15.5 kDa, which binds 
to the C/D motif32-36. This could reflect the presence of common binding domains or a 
common ancestry32-36.  Once the target RNA is selected through complementarity, 
pseudouridine is synthesized at the polyribonucleotide level through the action of the 
pseudouridine synthase, DKC1, which catalyzes the site-specific isomerization of the 
uridine to pseudouridine24 (Figure 1.1B).  This has been confirmed by the presence of a 
three-signature sequence element that is conserved among pseudouridine synthases 
and in yeast experiments where global disruption of Ψ synthesis occurred when Cbfp5 
(the yeast ortholog of DKC1) was mutated.   
Pseudouridine was discovered in 1951 and is the most abundant post-
transcriptionally modified nucleotide. It is formed by the isomerization of uridine under the 
action of DKC1.  It is unique among modified nucleosides in that it has an inert C-C rather 
than the usual N-C glycosyl bond that links base and sugar (Figure 1.1B).  The 
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irreversibility of this modification suggests distinct roles of pseudouridine in response 
to stimuli or stresses.  Pseudouridylation results in an extra hydrogen-bonding donor site 
on the non-Watson Crick face (Figure 1.1B).  The additional hydrogen bonding of Ψ-NH1 
to the 5’-phosphate oxygen atoms increases the backbone rigidity, and the number of 
interactions critical for inter- and intramolecular binding. Additionally, it leads to increased 
rotational freedom about the glycosyl bond, increased base pairing and enhanced local 
RNA stacking in both single-stranded and duplex regions resulting in a more stabilized 
and structurally rigid rRNA species that is critical for ribosomal stability and function10,14,37-
47.   
Ribosomal RNA (rRNA) and spliceosomal RNA are the main substrate of SNORAs 
with around 100 pseudouridylation events documented in rRNA alone (Figure 1.2A-B) 25-
27.  Modifications in rRNA can hypothetically affect any stage of ribosome synthesis, 
ribosome activity, and turnover of the ribosome. Changes can also be expected in RNA 
folding kinetics, conformational stability of individual and global folding domains, and in 
the activity of the final RNA.  Of these, improved base stacking is considered to be  the 
most important contributor to the stabilization of  RNA structure39,42,48,49.  Ribosome 
crystal structures have made it possible to catalog the known nucleotide modifications in 
rRNA in a three-dimensional sequence specific context47,50,51.  The resulting 2/3-D maps 
show that ribosome regions known or predicted to be important for function are rich in 
pseudouridylation modifications. About half of the known SNORAs do not have known 
rRNA targets and are considered “orphan”  suggesting functions other than rRNA-
pseudouridylation28,29.  
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It was recently shown that the physio-chemical properties of RNA and cellular 
functions can be altered with the incorporation of pseudouridine52.  The same study 
showed that pseudouridylation could be induced by stress52.  Other studies reported 
that the pseudouridination of multiple sites in synthetic RNA molecules results in an 
increased protein expression level53-55. Additionally, artificially incorporated 
pseudouridine in mRNAs mediates nonsense-to-sense codon conversion by facilitating 
unusual base pairing in the ribosome decoding center, thus demonstrating the potential 
regulatory role of pseudouridine and a new means of generating protein diversity53-55. 
 
C/D Box snoRNAs  
The second major class of snoRNAs, C/D box snoRNAs (SNORDs) are typically 70–90 nt 
long.  They provide a scaffold on which assembles a protein complex that includes 
NHP2L1 aka 15.5k, SNU13), NOP56, NOP58, as well as the methyltransferase 
fibrillarin, which facilitates the transfer of a hydroxyl group from S-adenosyl methionine 
(SAM) to its selected target nucleotide56-60.  The secondary structure of SNORDs are 
characterized by the C (RUGAUGA) and D (CUGA) boxes located near the 5' and 3' ends 
of the snoRNA(Figure 1.1C)33,61,62.   Additionally, short regions in up to two antisense 
boxes of approximately 5 nucleotides located upstream of the C box and downstream of 
the D box bind in a complementary manner to a rRNA target guiding its site specific 2′-O-
methylation57,58.   Interestingly, C/D snoRNAs are expressed as two distinct forms 
differing in their ends with respect to boxes C and D and in their terminal stem length.  
The long forms are more dependent than the short forms on the expression of the core 
snoRNP protein NOP58, and a subset of short forms are dependent on the splicing factor 
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RBFOX2.  Structural analysis of the potential secondary structure suggests that the k-
turn motif required for binding of NOP58 is less stable in short forms which are thus less 
likely to mature into a canonical snoRNP.  
This 2′-O-methylation modification induces structural changes leading to altered 
steric properties, increased structural rigidity, altered solution energy, preferred 3′ endo 
configuration and reduced hydrolysis of internucleotide bonds that help ensure ribosomal 
stability and function40,43,46,63.  This modification promotes increased stability in RNA 
conformations and alters the hydration sphere around the oxygen resulting in the 
blockage of sugar edge interactions, thus affecting the ability of the ribose to participate 
in hydrogen bonding interactions64,65. 
The majority of SNORDs do not have known rRNA targets based on sequence 
complementarity and are considered “orphan”  suggesting functions other than ncRNA-
methylation or cleavage28,29. Many of these orphan snoRNAs are in complexes devoid of 
the methylase fibrillarin66.  Conversely, some of the SNORDs found in the fibrillarin-free 
fraction were known to act in rRNA methylation, indicating that SNORDs can have dual 
functions. The association of SNORDs with proteins other than fibrillarin, NOP56/58 and 
15.5 has previously been demonstrated for SNORD115, which binds to hnRNPs and can 
be biochemically separated in fractions containing and lacking fibrillarin67.  Together, 
these data indicate that a given SNORD can assemble into protein complexes containing 
a methylase (‘methylating complexes’) and into complexes lacking a methylase (‘non-
methylating complexes’). 
In both methylating and non-methylating complexes, the SNORDs are protected 
from degradation by the associated proteins.  These different complexes might also 
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explain the occurrence of snoRNA fragments, which were first identified by RNAseq and 
later also validated by RNase protection68-70.  These processed snoRNAs (psnoRNAs) 
are most prevalent for SNORD115 and SNORD116, which play a role in Prader-Willi 
syndrome, and the SNORD113, -114 families as well as SNORDs- 50, 19, 32B, 123, 111, 
72 93, 23 and 8569-73.  Therefore, there are compelling reasons to suspect that SNORDs 
can fulfill new molecular functions different from rRNA modification.   Interestingly, these 
are clustered primarily in two imprinted loci on chromosomes 14 (DLK-DIO3 locus) and 
15 (SNURF-SNRPN locus).   
 
snoRNA biogenesis 
Eukaryotic cells exhibit significant differences in genetic organization and therefore 
mechanisms of snoRNA biosynthesis.   Only a select few vertebrate snoRNAs- the gene 
for the telomerase RNA component (TERC)  and (SNORD3 or SNORD8) that are 
primarily involved in rRNA processing (no modification function)- are transcribed as 
independent gene units with their own promoter74,75.  Of note, in yeast nearly all snoRNAs 
identified are produced in this manner.  In these cases, the precursor transcripts are m7G-
capped and also carry 3′ extensions.  Maturation at the 3′-end requires exonucleases as 
in the case of intronic snoRNAs, while maturation at the 5′-end occurs either via 
endonucleolytic cleavage, or via the formation of an hypermethylated m2,2,7G cap (TMG) 
by the enzyme TGS176,77.  Hypermethylation is also coupled tightly with assembly since 
TGS1 is recruited by the core proteins NOP56/NOP58 for C/D snoRNAs, and DKC1 for 
H/ACA snoRNAs78,79.  In the case of plants, snoRNAs are generated from polycistronic 
transcripts allowing for the processing of multiple snoRNAs.  On the other hand, in 
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vertebrates, all of the snoRNAs that guide nucleotide modifications are located within 
introns of genes transcribed via RNA polymerase II.   In fact, many of the snoRNAs are 
embedded within introns of genes that are involved in ribosome biogenesis80,81.  
 Most snoRNAs are encoded in introns and the pre-snoRNA sequences are 
liberated from the primary transcript by exonucleases7,82-84.  This entire process has not 
been fully characterized in humans.  For human box C/D snoRNAs, there is a preferential 
intronic location situated 50 nucleotides upstream of the branch-point, and Aquarius, was 
proposed to couple recruitment of snoRNP core proteins with splicing of the host pre-
mRNA85.  For box H/ACA, two conserved proteins, NAF1 and SHQ1 are specifically 
required for the assembly and stability of box H/ACA RNAs, without being part of the 
mature particles86-90.   These two factors are nucleocytoplasmic shuttling proteins that 
localize to the nucleoplasm and are excluded from the nucleoli and Cajal bodies86-90.  
Exonucleolytic processing begins after endonuclease cleavage, splicing and intron 
debranching to remove excess nucleotides from either end91-94. Poly(A)-specific 
ribonuclease, PARN, is a homodimeric 3′ exonuclease that reported plays a role in the 
processing of H/ACA box snoRNAs76.  The noncanonical poly(A) polymerase PAPD5 
adds oligo(A) tails to the last few nucleotides remaining after exonucleolytic degradation 
of the 3′ flanking intron and these oligoadenylated processing intermediates are then 
trimmed by PARN76.  It is well established though that mature snoRNA sequences are 
protected from exonuclease digestion by binding to the snoRNP proteins and, if present, 
by the 5′ cap9,11,18,95.  Signal sequences within the snoRNAs centered at boxes C and D 
or H and ACA direct binding of protein interacting partners that represent the functional 
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snoRNP complex96.  Interaction and assembly of these protein-RNA complexes are 
required for the proper processing and localization of snoRNAs. 
 
Expression of snoRNA   
The expression of small nucleolar RNAs (snoRNAs) was determined using high-
throughput quantitative PCR, microarray analysis or standard RNA-seq technologies97-99.  
Microarrays are unable to identify novel sequences or resolve the expression of snoRNAs 
in families with highly homologous members100.  Standard RNA-seq is generally limited 
to RNA species >200 nucleotides in length, and thus does not reliably detect most 
sncRNAs, including snoRNAs.  Additionally, these approaches are unable to distinguish 
the primary transcript from the mature snoRNA and as such the early reported snoRNA 
quantifications might not have been optimal.  
Several studies have used these methods to characterize snoRNA expression in 
leukemia.  Valleron et al., used microarray analysis to report that snoRNAs are 
differentially regulated in healthy samples compared with malignant T-cell populations 
and that in addition to a global down-regulation of these molecules, specific signatures 
may have prognostic significance in peripheral T-cell lymphoma (PTCL)101. Interestingly, 
they reported a specific signature in acute promyelocytic leukemia (APL) with ectopic 
expression of SNORD112-114 snoRNAs located at the DLK1-DIO3 locus99.   
Recently Zhou at al., used microarrays and reported that that fusion oncoproteins 
such as RUNX1T1-RUNX1 (also known as AML1-ETO) and MLLT3-KMT2A (also known 
as MLL-AF9) contribute to AML development by upregulating the expression of a distinct 
subset of snoRNAs that promote leukemogenesis via enhanced formation of snoRNA 
           11
 
 
ribonucleoprotein complexes, induction of rRNA methylation, increased protein 
translation, and possibly other mechanisms102. 
Given the deficiencies of hybridization methods, we developed approaches to 
ensure that we addressed the shortcomings addressed above.   As described in the next 
chapter, we took advantage of the fact that snoRNAs contain a free 3'-hydroxyl group, 
which allows for efficient ligation to sequencing adaptors allowing for their capture and 
efficient sequencing.   We also developed a novel analysis pipeline that maps areas of 
contiguous alignment in the genome, forming ab initio "clusters" representing snoRNAs.  
Taken together, these approaches provide a reproducible and verifiable way to quantify 
snoRNAs. We used these optimized approaches to determine the expression of snoRNAs 
in AML and report our findings in subsequent chapters. 
 
Role of SNORNAs in ribosome biogenesis.   
Ribosomes are complex macromolecular machines that underlie the translation process, 
allowing the conversion of data encoded within mRNA into proteins.  The human 80S 
ribosome (named for its apparent sedimentation velocity) is a ribonucleoprotein complex 
that comprises two ribosomal subunits, a large 60S subunit (LSU) (containing the 5S, 
28S, 5.8S rRNA, and 46 ribosomal proteins (r-proteins)) and a small 40S subunit (SSU) 
(containing the 18S rRNA and 33 r-proteins)103,104.   Ribosome biogenesis occurs in the 
nucleolus to form functional ribosomes critical for translation, cellular homeostasis and 
normal hematopoiesis (Figure 1.3).  It is one of the most energetically demanding105 of 
activities of the cell and appears to be a process of extraordinary complexity to generate 
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a machine capable of reading and interpreting the genetic code to produce functional 
proteins necessary for life103,104.  
Several regions of the ribosome are worth noting.  The SSU contains the mRNA 
entry and exit sites, the path along which the mRNA travels and the decoding center at 
the heart of which codons are read106.  The LSU is responsible for peptide bond formation 
and contains the polypeptide exit tunnel. It also has the ribozyme function required to 
catalyze peptide-bond formation and ensure mRNA decoding, as well as protein quality 
control107.  Importantly, several contact points called inter-subunit bridges, formed of both 
rRNA and RPs, ensure the assembly of the 80S ribosome and the dynamic coordination 
between the subunits during translation108-112.  Through all of this snoRNA modified 
rRNAs are essential for the function of the individual subunits and their ability to function 
collectively thus ensuring translation fidelity.  
 Three of the mature rRNA species, the 18S, 5.8S and 25S, are co-transcribed by 
RNA polymerase I (Pol I) as a single polycistronic transcript that is matured through a 
series of nucleolytic processing steps.  Maturation of the rRNAs and recruitment of the r-
proteins occurs within a series of precursor ribosomal particles, or pre-ribosomes within 
the nucleolus, nucleoplasm and cytoplasm.  The systematic purification of pre-ribosomes 
in yeast models has allowed the protein and rRNA composition of multiple intermediates 
to be elucidated and ordered into a ribosome assembly map113.  The plethora of assembly 
factors, ATPase, GTPase, helicase, kinase or nuclease activity, then orchestrate the 
ordered modification, folding and processing of rRNA, and the sequential recruitment of 
r-proteins103,114,115.  A few snoRNAs (SNORD3, SNORD8) have been shown to play a 
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role in the processing of rRNA by base-pairing with the pre-rRNA which brings the critical 
sites into close proximity and conformation framework that supports cleavage116-126. 
As the transcript emerges, many snoRNPs mediate the co-transcriptional covalent 
modification of over 100 rRNA residues127.  The function, dynamic folding and stability of 
these rRNA species are modulated by the post-transcriptional modifications, including 
pseudouridylation by H/ACA snoRNAs and 2’-O-methylation by C/D snoRNAs60,128.  
rRNA is the main substrate of snoRNAs and approximately 116 2′-O-methylation and 
around 107 pseudouridylation modifications have been reported in rRNA25,26,129-131. 
Modified rRNA nucleotides display altered steric properties and hydrogen bonding 
abilities that cumulatively act to stabilize the overall structure and conformation of the 
rRNAs and therefore the ribosome, allowing it to ensure translational fidelity118-121,125,126.  
Nuclear maturation of the pre-60S subunits, and pre-40S particles requires a large 
inventory of biogenesis factors, which associate and dissociate throughout the maturation 
process132.  Ribosomal subunits are then transported to the cytoplasm for their final 
maturation.  A series of stepwise processes occur in the cytoplasm under the action of 
biogenesis factors to convert the inactive pre-60S and pre-40S subunits, into functional 
subunits.  An active surveillance system exists that recognizes aberrant or stalled pre-
ribosomes and targets them for degradation thus excluding them from export to maintain 
translation fidelity133.  Once fully matured, both cytosolic ribosomal subunits are 
competent to engage in the translation of mRNA108. 
Cells tightly regulate their quantity of ribosomes by controlling rDNA transcription 
through a number of pluripotency-associated factors that interact with RNA Pol I or with 
rDNA promoters (in stem cells), while in differentiated cells, rDNA transcription is 
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controlled by scarcely expressed co-transcription factors, such as lineage-specific 
factors134.  Additionally, several oncogenic pathways and oncogenes have been reported 
as key activators of ribosome biogenesis. The mammalian target of the rapamycin 
complex (mTOR) is a protein kinase which is activated by nutrients, hormones and 
oncogenic signaling pathways and other stimuli. mTOR directly stimulates RNA Pol I and 
RNA Pol III by interacting with their promoters.  In addition to regulating ribosome amount 
in cells, mTOR regulates translation of mRNAs that contain 5’-TOP elements in their 
5’UTR135,136.  Since all of the mRNAs coding for RPs contain a 5’-TOP, mTOR positively 
regulates synthesis of RPs allowing a coordinated synthesis of the different components 
of the ribosome135,136.  This allows for coordination of ribosome biogenesis since most 
snoRNAs are encoded in RP host genes and some are thought to play a role in 
translation.  
Myc is another regulator of ribosome biogenesis through its effect on the 
transcription of many genes involved in cell cycle, apoptosis, efficiency of RNA Pol I 
transcription, RNA Pol III and the synthesis of RPs (by stimulating the transcription of 
RNA Pol II)137-139.  In contrast, some tumor suppressor genes (p53, BRCA1 and RB1) 
have been identified as inhibitors of ribosome biogenesis140,141.  Interestingly, p53 
represses the expression of FBL (methyltransferase responsible for rRNA 2’-O-ribose 
methylation) by binding directly to the FBL gene and inhibits the activity of the FBL 
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Role of rRNA modifications on ribosome-mediated regulation of translation  
Translation results in the synthesis of proteins corresponding to specific informational 
codes that are contained within mRNAs.  The regulation of the translational output is 
dependent on cell status, environment, development, and pathological conditions.  This 
regulation occurs through a dynamic interplay between cis-regulators (mRNA structures 
and/or sequences) and the translational machinery composed of its critical effector, the 
ribosome, and trans-regulators, (eukaryotic factors involved in initiation (eIF), elongation 
(eEF) and termination (eTF))143.  The role of the ribosome, as a key regulator of 
translation, with its hundreds of snoRNA induced modifications has recently become 
clearer leading to the idea of “specialized ribosomes”.  
rRNAs play a central role in translation, by directly underlying most of the key 
molecular interactions necessary for its fidelity.  The role of these post-transcriptional 
modifications on mRNA decoding, peptide-bond formation, and inter-subunit bridges 
have been well established106,144,145.  It has been reported that IRES-dependent 
translation initiation was directly affected by rRNA methylation.  It is well-known that 2’-
O-Me is more densely observed within the key functional rRNA domains such as the 
decoding center, the peptidyl transferase center (PTC), near sites involved in translational 
processes, including the A and P sites, the intersubunit bridges the peptide exit tunnel 
and intersubunit bridges implying that its presence might be playing a critical role25,47,146-
148.  2’-O-Methylation can contribute to ribosome population heterogeneity thus 
preferentially affecting several functional domains of ribosomes and impacting ribosomal 
activity25,47,146-148. 
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Pseudouridylation also plays a role on ribosome mediation of translation.  As 
discussed previously, DKC1 is the principal pseudouridinase, and in DKC1-depleted mice 
or X-DC patients with DKC1 mutations there is a loss of rRNA pseudouridylation.  The 
resulting alteration in ribosome function results in the decreased translation of mRNAs 
containing IRES elements, including the tumor suppressor p27 and the anti-apoptotic 
factors Bcl-xL and X-linked inhibitor of apoptosis protein (XIAP)125.   In fact, several 
studies reported that DKC1 inactivation, and thus rRNA pseudouridylation defects, are 
crucial for translational control and cell fate149-152.   Analysis at the atomic level of 
ribosome structures indicate that pseudouridylation contributes to rRNA folding in the 
vicinity of sites critical to ribosome interaction with tRNA and mRNA and necessary for 
translation fidelity153-157. 
 
Role of snoRNAs in splicing 
Spliceosomal snRNPs, U1, U2, U4, U5 and U6 are key components of the spliceosome 
and are absolutely required for pre-mRNA splicing (Figure 1.2A).  They are extensively 
modified, particularly in regions of functional importance in pre-mRNA splicing,  by small 
Cajal body-specific RNA (scaRNA) in Cajal bodies13.  Some scaRNAs are structurally 
indistinguishable from snoRNAs, whereas others combine C/D and H/ACA box motifs 
with other RNA parts158.   pre-mRNA splicing begins with a step-wise assembly of the 
spliceosome initiated by recognition of the 5' splice-site (5' SS) by complementary base-
pairing interactions with the 5'-end of U1 snRNA.   Through a series of coordinated events, 
the second step of splicing occurs, resulting in the production of mature mRNA and the 
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release of the excised intron (and possible snoRNA) and the U2, U5 and U6 snRNPs, 
which are then recycled for further rounds of pre-mRNA splicing.  
Modification of U2 has a direct impact on splicing efficiency.   Pseudouridylation of 
U35 within the branch site recognition region of U2 snRNA, has been demonstrated to 
direct the catalytic phase of pre-mRNA splicing and is required for pre-mRNA splicing. 
Interestingly, U35 is the nucleotide nearly opposite the branch-point adenosine. 
Biochemical, molecular data and biophysical data have clearly established links between 
spliceosomal snRNP biogenesis, spliceosome assembly, and splicing efficiency with the 
status of U2 snRNA modification indicating that U2 snRNA pseudouridylation is required 
for proper positioning of the 2'-OH of the branch-point adenosine so that it is accessible 
and exposed for recognition and nucleophilic activity54,159-162.  
SNORDs have also been implicated in alternative exon selection which controls 
the inclusion of exons and the retention of introns in mature mRNA thus increasing the 
diversity and complexity of the transcriptome163-165.   By way of examples, the neuron-
specific SNORD115 promotes the inclusion of an alternative exon in the serotonin 
receptor 2C pre-mRNA and SNORD88C regulates alternative splicing of FGFR3 pre-
mRNA66,68,72,166,167.  The mechanism underlying this process is not clear. 
 
snoRNAs are critical mediators of metabolic stress 
In a study aimed at identifying genes critical for the lipotoxic response, Schaeffer et al.,  
performed a genetic screen in Chinese hamster ovary (CHO) cells using retroviral 
promoter trap mutagenesis to create single gene disruptions and positive selection for 
survival under lipotoxic growth conditions168.  Unexpectedly, they discovered that three 
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highly conserved box C/D snoRNAs U32a (SNORD32a), U33 (SNORD33), U34 
(SNORD34), and U35a (SNORD35a) embedded within the rpL13a introns play a key role 
in the regulation of metabolic stress in mammalian cells possibly through their cytosolic 
function. Loss of these snoRNAs also altered mitochondrial metabolism and lowered 
reactive oxygen species tone169.  The rpL13a locus is highly conserved across species 
and is a constituent of the 60S ribosomal subunit that contributes to regulation of peptide 
production and catalysis of peptide synthesis.  
Separately, it was reported that inflammation stimulates secretion of the 
Rpl13a snoRNAs SNORD32a, SNORD33, SNORD34, and SNORD35a from cultured 
macrophages, mice, and human subjects170.  These snoRNAs co-fractionate with 
extracellular vesicles and are taken up by recipient cells traveling through the circulation 
to function in distant tissues170.  Previously snoRNAs were considered as housekeeping 
genes169.  This study and others continue to expand the repertoire of snoRNAs.  Here 
Schaeffer and co-workers provide evidence in support of a previously unappreciated link 
between inflammation and snoRNA secretion in mice and humans thus pointing to a 
potential role for secreted snoRNAs in cell-cell communication170.  Building on this, it was 
reported that SNORD60 is involved in intracellular cholesterol trafficking, which is 
independent on its suggested function in rRNA methylation171.  These findings reinforce 
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snoRNAs play a functional role in hematopoiesis  
AML is characterized by the rapid growth and accumulation of abnormal myeloid leukemia 
blasts in the bone marrow and blood172.  It is well known that this differentiation block is 
facilitated by somatic gene mutations, recurring chromosomal transformations, metabolic 
impairment, epigenetic changes and aberrant ncRNA expression leading to increased 
self-renewal, increased cell survival and impaired differentiation173.  It is unknown whether 
the snoRNA transcriptome plays a role in this process. Recently, Bellodi et al., reported 
that perturbations in H/ACA snoRNA modulated by DKC1 activity plays a functional role 
in hematopoietic stem cell differentiation174.  Interestingly, they showed that DKC1-
deficient human CD34 cells have an in vitro differentiation block relative to normal CD34+ 
even in the presence of a complete panel of cytokines that foster differentiation. Of note, 
this phenotype is rescued by DKC1WT expression and not by the catalytic mutant174.  
Hematopoietic stem cells have self-renewal capacity and can generate multipotent 
progenitors that can differentiate into lineage-committed myeloid and lymphoid 
progenitors giving rise to mature effector blood cells. These stem cells require a regulated 
protein synthesis rate and output and as such reports that ribosomal defects impair 
hematopoietic function are not surprising175,176. Intriguingly, aberrant ribosomal 
biogenesis and ribosomopathies are associated with increased cancer risk177-180.  Despite 
its critical role in ribosomal biogenesis, the full role of snoRNAs in physiologic and 
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snoRNAs are Involved in neoplastic transformation.  
Although snoRNAs are considered housekeeping genes, many of them have been 
recently identified with broader roles, including in genetic disorders, human variation, 
hematopoiesis, metabolism and neoplastic transformation151,168,181-184.  snoRNAs have 
been studied and implicated in cancers of almost all major organs: the lung182,185-187, colon 
and rectum188,189, breast190, B and T cell lymphoma101,191 and leukemia99,192 and the role 
of snoRNAs in cancer and disease has been extensively reviewed elsewhere184,193-196. 
Differently expressed snoRNAs were first linked to cancer in a human meningioma 
study where SNORA h5sn2 was reported to be highly expressed in normal brain but was 
decreased dramatically in meningioma197.  Other studies that looked at the expression 
of snoRNAs have demonstrated that their expression is altered in cancer and might be 
therapeutic targets. Oncogenic snoRNA42 has been identified at a locus commonly 
amplified in solid tumors and was subsequently reported to be commonly overexpressed 
in NSCLC 198-200.  In another NSCLC study, snoRNA silencing led to inhibition of cancer 
cell growth, proliferation and tumorigenesis by initiating caspase-3 dependent apoptosis 
while overexpression increased cell growth and colony formation182.  Changes in the 
expression of SNORD27, -30, -25, and -31 mark the progression of smoldering multiple 
myeloma201, and SNORD50 deletions are associated with prostate and breast cancer202-
204.  The differences are not just in the expression of a specific snoRNA.  Genome-wide 
comparison of SNORD expression between cancer and normal cells showed the 
presence of two classes of SNORDs that differ in their terminal stem length but are made 
from the same SNORD hosting intron28.  Ravo et al. described the aberrant expression 
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of the H/ACA snoRNA, SNORA3 in endometrial cancer and its presence as part of an 
sncRNA endometrial cancer signature205. 
Recently, the aberrant expression of snoRNAs along with altered Rb/p16 
regulation was reported in AML as compared to healthy blood samples99,206.  Specific 
snoRNA prognostic and diagnostic signatures were noted in leukemic subgroups raising 
the possibility that snoRNA expression was regulated in a cell type specific manner 99,206.  
All of this raises the possibility that snoRNAs might play an expanded role in AML. 
 
Multiple Myeloma 
Multiple myeloma (MM) is an incurable malignancy of antibody secreting plasma B cells 
characterized by the t(4;14)(p16.3;q32.3) translocation in 20% of cases and is associated 
with reduced patient survival207. The t(4;14) translocation upregulates the MMSET 
proteins which hosts a novel orphan box H/ACA class snoRNA within intron 19.  In a 
recent study, t(4:14) positive and negative MM patient tumor cells were interrogated by 
RNA sequencing.  The H/ACA snoRNA ACA11 was found to be highly expressed and 
sufficient to down regulate ribosomal protein gene expression, suppress oxidative stress 
and increase proliferation of MM cells207.  They reported a signature of up regulated genes 
involved in mitochondrial respiration and oxidative stress. They found that ACA11 
overexpression leads to the increased oxidative stress in primary splenic B-cells, 
established myeloma cell lines, as well as embryonic fibroblasts207.  In particular, cells 
overexpressing ACA11 showed enhanced proliferation, significantly larger colony sizes 
in soft agar assays, and elevated ERK1/2 phosphorylation, a downstream consequence 
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of oxidative stress.  Thus, the changes in gene express driven by ACA11 overexpression 
may play a pivotal role in the development and/or progression of multiple myeloma207.  
In previous studies, a translocated allele (TKO) model system was used to prove 
the oncogenic effect of MMSET in myeloma thus shifting the pathogenic importance from 
MMSET to ACA11.  A recent report suggested that MMSET and not ACA11 is the key 
pathologic mediator in t(4;14) myeloma208.  This study raises some interesting questions 
but it may be that ACA11 has an important role in t(4;14) pathogenesis given that it is in 
the MMSET locus, and often, intronic RNA are found to be involved in the same 
biochemical pathway as their host gene74,208.  Interestingly in another study, it was 
reported that ACA11 promoted cell growth, migration and invasion through activation of 
the PI3K/AKT pathway, subsequently increasing cyclinD1 expression and inducing 
endothelial to mesenchyme transition209. 
 
Dyskeratosis Congenita 
Dyskeratosis congenita (DC) is an inherited disorder characterized by bone marrow 
failure, cancer predisposition, additional somatic abnormalities, and shortened telomeres.  
The most common reported form of DC is the X-linked form, which is due to loss-of-
function mutations of DKC1, encoding dyskerin210,211. Dyskerin is a 58kD nucleolar protein 
that is the catalytic component of the H/ACA snoRNP responsible for the isomerization of 
uridine to pseudouridine166,212-214.  It was initially assumed when DKC1 was identified as 
a cause of DC that a loss of fidelity in pseudouridylation or ribosome biogenesis was 
responsible for the disease phenotype.  However, it was discovered that dyskerin binds 
to telomerase RNA, which is a critical part of the telomerase enzyme and acts as a 
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template for the synthesis of the TTAGGG repeats that are found at the telomeres of all 
chromosomes215.  Of note, genetic alterations in autosomal dominant forms of DC also 
result in impaired telomere maintenance.   
In humans, all H/ACA snoRNAs are encoded within introns of pre-mRNAs and the 
processed mature RNAs are devoid of a 5′ cap structure212,216.  On the other hand, human 
telomerase RNA (TERC) is transcribed by RNA polymerase II (pol II) from its own 
promoter and the mature RNA (451 nt) bears a TMG-cap at the 5′ end. TERC contains a 
H/ACA snoRNA-like sequence at its 3’end that binds dyskerin and the 3 other H/ACA 
proteins and assists in the assembly of telomerase in Cajal bodies and its translocation 
to the telomeres215,217-220.  While the H/ACA domain of TERC does not guide 
pseudouridylation, it is essential for its stability and accumulation in vivo221,222.  Like 
scaRNA, telomerase RNPs are localized in Cajal bodies and contain a specific sequence 
motif, the CAB box, in the terminal loop of the conserved region 7 (CR7) that is necessary 
for their import into Cajal bodies13,217-219,223.  The presence of DNA damage foci at the 
telomeres in mouse cells carrying DKC1 mutations that are known to be pathogenic in 
humans has been reported224,225.  This suggests that the presence of mutant dyskerin in 
the active telomerase complex  may cause a transient capping defect at telomeres, 
leading to telomere loss226.   
Although there are no indications that ribosome biogenesis is affected in DC 
patients, studies of mice with DKC1 mutations suggest that defects in ribosome 
biogenesis or pseudouridylation may contribute to the DC phenotype seen in 
humans125,226-228.  The mechanism connecting the mutations in dyskerin to telomere 
shortening and lower levels of TERC has not been fully elucidated228-231. 
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Role of C/D box snoRNAs in the pathogenesis of core binding factor APML. 
Approximately 4%-12% of adult and 12%-30% of pediatric acute myeloid leukemia (AML) 
patients and up to 40% of those classified by the French-American-British system (FAB) 
as M2 subtype contain the t(8;21) translocation that gives rise to the AML1/ETO fusion 
oncoprotein (also known as RUNX1-RUNX1T1)232.  It represents the most frequent 
chromosomal anomaly in leukemia (18–20%)233,234.  The resulting fusion consists of the 
N-terminal DNA-binding domain of AML1(initial 177 amino acids of AML1), a required 
transcription factor for hematopoiesis, and almost all of ETO, a protein known to function 
as a corepressor for a variety of transcription factors235.  These AML, together with AML 
cases carrying mutations in CBFB, are referred to as core binding factor AML and are 
thought to share a common pathogenetic mechanism.   
It is well established that that AML1/ETO impacts multiple processes involved in 
normal myelomonocytic development where the fusion protein interferes with multiple 
signal transduction pathways, thus promoting early myeloid cell self-renewal and 
interfering with proper hematopoietic differentiation236.   AML1/ETO also directly 
interferes with recruitment of essential cofactors by a number of crucial hematopoietic 
transcription factors such as C/EBPα and PU.1, thus potentially blocking differentiation of 
myeloid progenitors.   AML1-ETO fusion is an active repressor that recruits a multi-protein 
complex including HDACs to AML1 target genes.   Both human and mouse models of 
AML have clearly demonstrated that AML1-ETO is insufficient for leukemogenesis in the 
absence of secondary events235. 
A recent paper reported that leukaemogenesis by AML1-ETO required expression 
of the groucho-related amino-terminal enhancer of split (AES) which functioned by 
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inducing snoRNA/RNP formation through interaction with the RNA helicase DDX21102. 
They reported that expression levels of C/D box snoRNAs in AML patients correlated 
closely with in vivo frequency of leukaemic stem cells, indicating that C/D box snoRNAs 
contribute to the regulation of leukemia-initiating activity102.   Of note, the increased in C/D 
box snoRNA expression was reportedly accompanied by increased ribosomal RNA 
methylation and protein translation.   Interestingly, they also reported increased C/D box 
snoRNA expression in AML driven by MYC or MLL-AF9. The authors suggested that 
increased translation is a direct consequence of oncogene expression.  This finding 
contrasts with other studies that report that disease stem cells exhibit reduced levels of 
translation237,238.    However, as detailed in chapter 3, we show that C/D box snoRNA 
expression is not consistently elevated in AML expressing AML-ETO or MLL fusion 
genes.  
 
Dysregulation of DLK-DIO3 locus snoRNAs in acute promyelocytic leukemia 
The DLK-DIO3 locus located on human chromosome 14 (14q32) is an imprinted locus 
that contains the protein-coding genes DLK1, Rtl1, and Dio3 expressed from the 
paternally inherited chromosome.   The maternally inherited chromosome produces a 
large number of ncRNAs, including MEG3, MEG8, the largest miRNA cluster in the 
human genome (with 54 miRNAs), and a large cluster of C/D box snoRNAs.   The genes 
in this locus are thought to be developmentally regulated and expressed in a range of 
embryonic and extraembryonic cells types with postnatal expression being found 
predominantly in the brain.  The snoRNA genes within the DLK-DIO3 locus are tandemly 
repeated C/D snoRNAs.  They are thought to arise from the processing of a single long 
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transcript originating from the MEG8 gene239.  The DLK-DIO3 locus C/D box snoRNAs 
are orphan snoRNAs, in that they have no known target mRNAs, although some targets 
have been ascribed based on nucleotide complementarity240,241.  Allele-specific 
expression of the locus is mainly regulated by three methylated DMRs: the IG-DMR, 
DLK1-DMR, and the MEG3-DMR.  
Using microarrays to analyze three cases of APML, Valleron and coworkers first 
reported that expression of DLK-DIO3 snoRNAs was increased.  This overexpression 
was in contrast to the reduced expression in normal karyotype AML.  Two other studies 
have confirmed this finding97,242.  Interestingly, increased expression of DLK-DIO3 
snoRNAs also is present in APML carrying variant RARA-fusion partners, suggesting that 
aberrant retinoic acid receptor signaling is likely responsible for the altered snoRNA 
expression.  Although controversial, Manodoro et al., reported that altered DNA 




As detailed in chapter 4, we have identified differential expression of SNORA21 in AML.  
Here, we review literature, mostly derived from studies of yeast, implicating SNORA21 as 
a key snoRNA regulating rRNA biogenesis and function.   
In yeast, there are approximately 50 known Ψ sites occurring mainly  in ribosome 
regions known to be functionally important, including the PTC47,118.  To study the effect of 
Ψ modification on rRNA function in these critical regions, researchers characterized the 
impact of the genetic deletion/inactivation of individual or several snoRNAs on cell growth 
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and ribosome function.  In a landmark study, King and coworkers targeted 5 snoRNAs 
modifying six positions within the PTC118.  Deletion of snR10, the yeast ortholog of 
SNORA21, resulted in a loss of Ψ at position 2919 in the rRNA PTC and impaired cell 
growth22,23.  Using luciferase protein expression and [35S]methionine incorporation, they 
showed that  the rate of protein synthesis was reduced by 20% in yeast lacking snR10.  
They also reported a reduced yield of polysomes and elevated 80S peak, reflecting a 
defect in the translation cycle, with fewer translating ribosomes at steady state118.  
Their summary finding that loss of snR10 (SNORA21) results in slow growth, 
impaired production of small subunits, loss of Ψ2919 (Ψ 4470), an altered polysome 
pattern, and a reduced rate of protein synthesis has implications for humans given the 
evolutionary conservation and function of the ribosome.  Strikingly, the patterns observed 
for snR10 were not observed with the deletion of snoRNAs individually. 
Other studies have corroborated these findings244 and extended27,244 them to take 
a more intimate look at translation in the context of snoRNA loss. Using similar assays, 
Baxter-Roshek  and coworkers reported changes in reading frame maintenance, 
nonsense suppression and altered aa-tRNA selection128.  They concluded that certain 
rRNA modification fine tune the structure of the A-site region of the large subunit so as to 
assure correct positioning of critical rRNA bases involved in aa-tRNA accommodation into 
the PTC, of the eEF-1A•aa-tRNA•GTP ternary complex with the GTPase associated 
center, and of the aa-tRNA in the A-site128.  These findings are in line with the known 
effects of pseudouridylation in altering folding patterns and stabilizing key RNA structures. 
Taken together, these findings represent a direct demonstration in support of the 
prevailing hypothesis that rRNA modifications mediated by snoRNAs serve to optimize 
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rRNA structure for production of accurate and efficient ribosomes critical to translation 
fidelity. 
 
 SNORA21 in human disease 
The increasing evidence that snoRNA play a central role in oncogenesis prompted 
Yoshida and others to interrogate publicly available datasets to identify differentially 
expressed and commonly upregulated snoRNAs in colorectal cancer (CRC). They 
identified SNORA21 (17q12) as a potential oncogenic snoRNA that is significantly 
upregulated in CRC245,246.  They showed that knock-down of SNORA21 in colorectal cell 
lines resulted in decreased cell proliferation and impaired migration245,246. 
Another study recently reported that SNORA21 expression was significantly 
upregulated in human gastric cancer and associated with metastatic disease247.  Using 
microarray data, Qin and coworkers recently reported that SNORA21 expression 
correlated with the proliferation, migration and invasion of gallbladder cancer cells.  
Knock-down of SNORA21 in cell lines resulted in increased expression of E-cadherin, 
decreased expression of N-cadherin and vimentin, increased apoptosis, and G1 growth 
arrest248.  In the non- small-cell lung cancer (NSCLC) setting Gao assessed SNORA21 
expression in 77 frozen NSCLC tissues and reported that high expression levels of 
SNORA21 were associated with poor overall survival185. 
Taken together these studies report increased expression of SNORA21 in several 
cancers with clinical consequences.   In chapter 2, we present the expression of snoRNAs 
in normal and aberrant hematopoiesis. In chapter 3, we expand on this work by describing 
the expression of snoRNAs in fusion and mutated splicing factor AML. Finally, in chapter 
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4, we characterize the effect of SNORA21 deletion on ribosome function, translation, and 
cell growth in leukemic cells.   
 




Figure 1.1 Modifications guided by box-C/D and box-H/ACA snoRNAs and the core associated proteins. A). The box 
H/ACA snoRNAs have an ACA motif at the 3′ end of the snoRNA and a hinge (H) box linking two stem structures. One or 
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both pseudouridylation pockets contains a bipartite antisense region of 9-13 nucleotides between its two strands. Watson-
Crick base pairing selects and localizes the target rRNA to the pseudouridine synthase. Ψ represents the targeted uracil. 
All SNORAs associate with the four proteins, as shown. B). Isomerization of uridine to pseudouridine catalyzed by DKC1. 
The uracil base in uridine (left) is linked through its N-1 position (arrowhead) to the C-10 position of the ribose. The base in 
U possesses one hydrogen-bond acceptor and one donor (dashed arrows; a and d, respectively). Isomerization occurs 
when the uracil base is rotated 180± through an N3–C6 diagonal axis (circular arrow). In pseudouridine (right), the C-5 
position of uracil (arrowhead) is linked to the C-10 position of the sugar, resulting in an increase in hydrogen bonding 
capacity (to one acceptor and two donors) compared with that in U. C). Schematic structure of a C/D box snoRNAs. The 
box C/D snoRNAs have conserved C- and -D boxes, flanked by short inverted repeats at the 5′ and 3′ ends. Adjacent to 
box D or D′, there is an rRNA antisense element of 10–20 nucleotides complementary to a specific region of the rRNA. The 
SNORD forms a protein complex made of 15.5 (also known as SNU13 and NHP2L1), NOP56/58 and 
the methylase fibrillarin (Fib) that 2′-O-methylates (H3CO-) rRNA at a defined position 5 nt upstream of the D or D′ box. D) 












Figure 1.2. snoRNAs modify key functional regions. A) U2 snRNA modification by snoRNAs is required for pre-mRNA 
splicing pseudouridines and 2'-O-methylated residues in human spliceosomal snRNAs. primary and secondary structures 
of human major spliceosomal snRNas (U1, U2, U4, U5 and U6) are shown. Pseudouridines are surrounded by rectangles; 
2'-O-methylations are circled. The thick lines indicate the nucleotides participating in RNA-RNA interactions or involved in 
catalysis during pre-mRNa splicing. The 5' caps (2,2,7 trimethylated guanosine cap for U1, U2, U4, U5 and γ-methylated 
guanosine cap for u6) are also depicted B) Modifications in the rRNA is critical for ribosome biogenesis. Blue oval- A site 
finger, purple- intersubunit bridge, green- peptidyl transferase center. 
 
  







Figure 1.3. Ribosome biogenesis. The mature 80S ribosome is composed of a 40S subunit containing 18S ribosomal 
RNA (rRNA) and 33 ribosomal proteins (RPs) and a 60S subunit containing 5S, 5.8S and 28S rRNAs and 47 RPs. The 
majority of steps in ribosome biogenesis occur in the nucleolus, where RNA polymerase I (Pol I) transcribes the 47S 
precursor rRNAs (47S pre-rRNAs) from ribosomal DNA genes, which contain the sequences of 18S, 5.8S and 28S rRNAs. 
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RPs are assembled into pre-40S and pre-60S ribosomal subunits in the nucleoplasm and the cytoplasm. The complete 












































Small nucleolar RNAs (snoRNAs) are noncoding RNAs that contribute to ribosome 
biogenesis and RNA splicing by modifying ribosomal RNA and spliceosome RNAs, 
respectively.  We optimized a next-generation sequencing approach and a custom 
analysis pipeline to identify and quantify expression of snoRNAs in acute myeloid 
leukemia (AML) and normal hematopoietic cell populations. We show that snoRNAs are 
expressed in a lineage- and development-specific fashion during hematopoiesis.   The 
most striking examples involve snoRNAs located in 2 imprinted loci, which are highly 
expressed in hematopoietic progenitors and downregulated during myeloid 
differentiation.  Although most snoRNAs are expressed at similar levels in AML cells 
compared with CD341, a subset of snoRNAs showed consistent differential expression, 
with the great majority of these being decreased in the AML samples.  Analysis of host 
gene expression, splicing patterns, and whole-genome sequence data for mutational 
events did not identify transcriptional patterns or genetic alterations that account for these 
expression differences.  These data provide a comprehensive analysis of the snoRNA 
transcriptome in normal and leukemic cells and should be helpful in the design of studies 












There has been increasing interest in the contribution of the noncoding transcriptome to 
the regulation of normal and malignant hematopoiesis.  Noncoding RNA (ncRNA) species 
are classified into 2 groups based on their sizes.  Long noncoding RNAs (lncRNAs) are 
>200 nucleotides, and they are expressed in a lineage-specific fashion in 
hematopoiesis249.  Recent studies have implicated lncRNAs in hematopoietic lineage 
commitment and control of self-renewal249.   Small noncoding RNAs (sncRNAs) are <200 
nucleotides and include a heterogeneous group of RNA species.  Best characterized are 
microRNAs (miRNAs), which are 19-26 nucleotide RNAs that repress translation of target 
RNAs by targeting them to the RNA-induced silencing complex.  MicroRNAs are also 
expressed in a lineage-specific fashion and have been shown to play key roles in the 
regulation of hematopoiesis250-252.  Other sncRNAs include small nucleolar RNAs 
(snoRNAs), small nuclear RNAs (snRNAs), small interfering RNAs, and Piwi-interacting 
RNAs.  With some exceptions, the expression of these other sncRNAs in hematopoietic 
cells and their contribution to the regulation of hematopoiesis are not well characterized. 
snoRNAs are a subset of sncRNAs that are involved in the posttranscriptional 
modification of ribosomal RNAs (rRNAs) and snRNAs.  These modifications are critical 
for a variety of cellular processes, including ribosomal biogenesis and splicing of RNAs. 
Classification of snoRNA species is based on the presence of highly conserved sequence 
elements that define 3 snoRNA families: H/ACA box (SNORAs), C/D box (SNORDs), or 
small Cajal body–specific RNAs (scaRNAs).  H/ACA and CD box snoRNAs target specific 
ncRNA species with base pair complementarity for site-specific pseudouridylation253 or 
2’-O-methylation,61 respectively. scaRNAs localize to RNA-containing Cajal bodies and 
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are responsible for the methylation and pseudouridylation of spliceosomal RNAs U1, U2, 
U4, U5, and U12.  There are also orphan snoRNAs, which lack known complementarity 
to rRNAs or snRNAs and therefore largely have unknown functions.  Recent studies have 
suggested an expanded role for snoRNAs beyond ribosomal biogenesis and 
modifications to snRNA.  For example, emerging data suggest that snoRNAs may 
contribute to alternative splicing,254 regulation of chromatin structure,255 metabolism,168 
and neoplastic transformation.204 
The contribution of snoRNAs to the regulation of normal and malignant 
hematopoiesis is largely unknown.   Chu et al reported that over- expression of the H/ACA 
box snoRNA ACA11 in t(4;14)-associated multiple myeloma contributes to myeloma cell 
proliferation and resistance to chemotherapy256.   Several groups have reported marked 
increased expression of snoRNAs contained in the DLK-DIO3 locus in acute 
promyelocytic leukemia, although their contribution to leukemogenesis is 
unknown97,99,242.  The lack of a method to accurately and comprehensively assess 
snoRNA expression has limited research in this area.  Array-based methods only 
interrogate a subset of snoRNAs and cannot distinguish between mature and precursor 
snoRNAs206,257.  To avoid sequencing very abundant rRNAs and transfer RNAs (tRNAs), 
most next-generation sequencing approaches to interrogate the transcriptome have 
focused on longer (>200 nucleotide) or very short (17-26 nucleotide) RNA species.  Thus, 
there is a gap in current transcriptome sequencing that includes most snoRNAs. To 
address this gap, we developed a next-generation sequencing approach optimized to 
interrogate sncRNAs, including snoRNAs.   We show that snoRNAs are expressed in a 
lineage- and development-specific fashion in human hematopoiesis with a subset of 
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snoRNAs that show consistent differential expression in acute myeloid leukemia (AML). 
We further show that expression of snoRNAs does not correlate with expression or 
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MATERIALS AND METHODS 
Fluorescence-activated cell sorting of hematopoietic populations 
Bone marrow aspirate samples were obtained from normal healthy donors after obtaining 
informed consent (institutional review board approval Washington University Human 
Studies Committee #01-1014).  Samples were processed via ammonium–chloride–
potassium red cell lysis, washed once in phosphate-buffered saline, and then stained for 
flow cytometry using the following antibodies: CD34-phycoerythrin (PE) (PE-pool, 
Beckman Coulter, IM1459U,  Brea, CA), CD14-allophycocyanin (BD Biosciences, clone 
M5E2, San Jose, CA), CD15-fluorescein isothiocyanate (BD Biosciences, clone HI98), 
CD16-PE (BD Biosciences, clone 3G8), CD33-allophycocyanin (eBioscience, clone WM-
53, San Diego, CA), CD3-V450 (eBioscience, clone OKT3), and CD19-PE (BD 
Biosciences, clone HIB19). Defined hematopoietic cell populations that were sorted 
included: promyelocytes (CD14-, CD15+, and CD16low/-),258 monocytes (CD14+), 
neutrophils (CD14-, CD15+, and CD16-),258 and CD34+ cells. Cells were sorted directly 
into lysis buffer, and RNA was isolated using the Quick-RNA Microprep Kit (Zymo 
Research, Irvine, CA). 
 
Small RNA library construction and sequencing 
The NEBNext Small RNA Library Prep Set for Illumina (New England BioLabs, Inc., 
Ipswich, MA) was used to prepare the libraries following the manufacturer’s specifications 
using 100 to 500 ng of total RNA as input259.  After adaptor ligation, reverse transcription, 
and polymerase chain reaction (PCR) amplification, the libraries were size selected on a 
Blue Pippin (Sage Science, Beverly, MA) to enrich for library molecules with inserts 
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between approximately 17 and 200 nucleotides.   The resulting libraries were sequenced 
on a MiSeq instrument to generate 150 bp, single-end reads.  All sequence data will be 
deposited in dbGaP. 
 
Bioinformatic analysis 
Sequencing data were trimmed to remove adapter sequences using cutadapt with the 
command “cutadapt -f fastq -a AGATCGGAAGAGCACACGTCT” and then mapped to the 
National Center for Biotechnology Information Build 37 human reference sequence using 
bwa mem260 with the custom parameters “bwa mem -M -k 15 -T 17” to obtain short 
alignments that result from small RNA species.   These alignments were then used in the 
following analyses to characterize the spectrum of RNA species captured by the library 
approach, identify novel RNA species, and quantify the expression of annotated 
snoRNAs. 
We first defined the distribution of RNA species captured in the library by annotating 
the sequencing reads from all samples with RNA biotypes from GENCODE version 19,261 
mirBase version 21262 and a previously described set of snoRNA annotations 
(snoRNAome241).  Given that the library preparation method has a 3’-end bias, reads were 
assigned to a single RNA annotation in a strand-specific manner based on the proximity 
of the read start position to the 3’ end of overlapping annotations.  Reads were called 
“unannotated” if the alignments were uncertain (ie, mapping quality of 0), or they did not 
map to any annotation in a strand-dependent manner. 
Next, we identified potentially novel RNA species using a custom Practical 
Extraction and Report Language (PERL) script designed to detect and annotate 
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aggregate read “clusters” using pooled sequence data from all normal hematopoietic cell 
and AML samples (N = 64).  Briefly, mapped reads for all samples with a mapping quality 
>0 were merged into a single BAM file, and regions with a minimum strand-specific read 
depth of 50 were extracted.  All reads spanning these regions were then merged to create 
strand-specific read clusters, which were trimmed such that the cluster edges were ≥ 20% 
of the maximum read depth (to separate closely spaced clusters that may have become 
merged by spurious “joining” reads), and subsequently filtered to retain those with an AT 
nucleotide content <80%  to  exclude  low-complexity  sequences.   The total number of 
clusters that resulted from this procedure was 6231.  Clusters were then annotated with 
read quality and mapping statistics (eg, mean mapping quality, number of unique read 
start positions, and mean number of mismatches with the reference sequence), the 
number of strand-specific read counts, and maximum depth across the cluster.  Cluster 
coordinates were compared with the GENCODE, mirBase, and snoRNAome annotations, 
and “tagged” with the strand-specific transcript or gene annotation with the best reciprocal 
overlap.  Potentially  novel  species  from  this  set  that  demonstrated <50% reciprocal 
overlap with known annotations and total counts ≥ 500 (N = 340 clusters) were then 
manually analyzed with the programs snoGPS and snoSCAN, which identify H/ACA box 
and C/D box snoRNAs with reported rRNA targets,263,264 and with snoReport for 
identification of all snoRNAs, including orphans265 as well as a custom script.  This 
produced a final list of 111 clusters that were identified as potential snoRNA species, 
which were manually reviewed using the Integrated Genome Viewer (version 2.3.40)266 
and the sno/miRNA track of UCSC Genome Browser267 to exclude low-quality clusters or 
those that overlapped known snoRNAs. 
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Finally, expression levels for a comprehensive set of annotated sncRNA species 
were generated for each sample using annotations curated from snoRNAome241 and 
miRBase268 along with all GENCODE version 19 annotations with biotype “snoRNA”. 
These annotation databases were combined to produce a set of 4931 nonoverlapping 
annotations, with snoRNAome and mirBase entries superseding those from GENCODE 
version 19 with overlapping coordinates.  Overlapping annotations from snoRNAome and 
mirBase were reviewed, and a single species was selected based on the correspondence 
between the sequencing reads at the locus and annotation; the other annotation was 
excluded.  Expression values for these annotations were then obtained with the 
featureCounts program269 using parameters for strand-specific counting and including 
only reads with a mapping quality of  ≥1.  These counts were normalized to the total 
mapped reads 3 x 106 for visualization and subsequent statistical analyses. 
 
Quantitative reverse transcription PCR of selected snoRNAs 
The extracted RNA was purified on a RNA Clean & Concentrator-5 column (Zymo 
Research) using the manufacturer’s >17- nucleotide-long protocol and resuspended in 
10.0 mL of nuclease- free water.  The Qubit RNA HS Assay Kit (Life Technologies, 
Carlsbad, CA) and the TapeStation system (Agilent, Santa Clara, CA) were used for 
quantification and quality assessment, respectively, according to the manufacturer’s 
instructions.  The RNA was reverse transcribed using iScript Reverse Transcriptase 
(BioRad, Hercules, CA) at 42°C, according to the manufacturer’s instructions.  The 
complementary DNA (cDNA) was PCR amplified using forward and reverse primers 
containing sequences specific to the snoRNAs (Table 2.1).  In a 20-mL reaction, 3.0 ng 
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of cDNA template, 0.5 mM each of forward and reverse primers (IDT, Chicago, IL), 10 mL 
iTaq Universal SYBR Green 23 Supermix, (BioRad), and nuclease-free water were cycled 
for 60 rounds at an annealing temperature of 60°C on a StepOnePlus Real-Time PCR 
System (Applied Biosystems, Foster City, CA).  The 5S rRNA was used to normalize 
snoRNA expression. 
 
Differential expression analysis 
Differential expression and hierarchical clustering analyses were performed with the 
Partek Genomic Suite (Partek, Inc., St. Louis, MO) using log2 (read count per million 
mapped reads 3 x 106 [RPM]) expression values for the curated sncRNA annotations as 
input270; only RNA species with mean normalized count values ≥5 were selected to 
produce reliable differential expression profiles.  Data were first assessed for normality, 
and differential expression analysis was performed with the Partek Genomic Suite using 
1-way analysis of variance (ANOVA) with estimation via the method of moments model271. 
The differential expression of snoRNAs and miRNAs in the AML patients vs normal 
hematopoietic stem/progenitors was based on a fold change >2 and P <0.05). 
 
Splicing analysis 
Intron junction counts for annotations in GENCODE version 19 were obtained from 
aligned BAM files using Tablemaker and Ballgown272 and normalized to the total number 
of junction reads observed 3 x 106.   The linear regression between normalized snoRNA 
expression (RPM) and the normalized expression for “host gene” junctions spanning each 
snoRNA were assembled in R273.  Correlations between all snoRNAs and junction 
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expressions were similarly performed. 
 
Somatic mutation of snoRNAs 
The coordinates of the 344 651 introns in the genome (GRCh37) and that of 402 snoRNAs 
were intersected with the coordinates of 367 904 prevalidation indels from 49 Cancer 
Genome Atlas AML patient samples using BEDtools274 and R. 
 
Statistical analysis 
Statistical analysis and graphing were performed with GraphPad Prism version 8.00 for 
Mac, (GraphPad Software, La Jolla, California) and R.  Error bars represent the standard 
error of the mean (SEM).  Significance was determined by 1-way ANOVA followed by 
Tukey multiple comparisons test.  Significance is denoted as: *P < .05; ** < .01; ***P < 



















Small RNA-seq pipeline 
We modified a previously described method for sequencing miRNAs to analyze more 
comprehensively the small RNA component of the transcriptome259 .A key aspect of this 
approach is the method used for cDNA library generation, which includes the addition of 
an oligonucleotide adaptor to the 3’-end of RNA molecules before reverse transcription. 
Importantly, this requires the presence of a free 3’ hydroxyl group on the RNA molecule. 
We then performed an expanded size selection to capture RNA species between 17 and 
200 nucleotides, which includes miRNAs, snoRNAs, and other sncRNAs, but excludes 
most messenger RNA (mRNA) and lncRNA molecules.  The sequence data obtained 
were analyzed using 2 complementary bioinformatic approaches to quantify both 
annotated and novel sno- and miRNAs (Figure 2.1A). 
We used this approach to interrogate the small RNA transcriptome in human 
hematopoietic cell populations from normal hematopoietic stem/progenitors and from 
diagnostic AML samples.  CD34 cells, promyelocytes, neutrophils, monocytes, T cells, 
and B cells were sorted by flow cytometry from the bone marrow of 6 healthy individuals. 
Data from primary AML samples were generated from bulk leukemic cells from 33 
treatment-naive patients with AML (Table 2.2).  Most of these cases (97%) had normal 
cytogenetics, and all were classified as intermediate-risk AML.  An average of 3.2 x 106 
reads was obtained across both normal and leukemic samples (Table 2.3).  Mapping of 
sequencing reads from all samples to annotation features from GENCODE version 19 
and snoRNA and miRNA annotations in the human snoRNAome and miRBase (see 
“Materials and methods”) demonstrated that snoRNAs were by far the most abundant 
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small RNA species present in our data (Figure 2.1B).  C/D box snoRNAs represented 
74.95% of all reads; H/ACA box snoRNAs and scaRNAs represented another 3.19% and 
0.34% of total mapped reads, respectively.  Small nuclear RNAs, which are involved in 
RNA splicing, were the next most abundant class of sncRNA, representing 10.19% of 
reads. miRNAs represented a relatively small percentage of all sequenced reads (1.48% 
of all mapped reads).  Reads mapping to unannotated regions of the genome accounted 
for 0.04% of all sequences. 
We next compared the expression of snoRNAs using data from our modified library 
protocol with expression levels obtained by standard total RNA sequencing (RNA-seq) 
(Illumina Tru-seq) and of the same tissue sample.  Relevant to this analysis, the majority 
of snoRNAs are embedded in the introns of host genes.  We observed that standard 
transcriptome sequencing cannot reliably distinguish unspliced primary host gene RNA 
from correctly processed snoRNA.  Typical results are shown for SNORA64, which is 
located in the intron of its host gene, RP32 (Figure 2.1C).  Whereas sequence reads 
corresponding to mature SNORA64 were readily identified using our pipeline, only low-
level reads that span the entire intron of RP32 were detected using total RNA-seq. 
Accordingly, the correlation of snoRNAs quantified using these 2 RNA-seq pipelines was 
poor (Figure 2.1D).  These data demonstrate the superiority of our small sequencing 
pipeline to quantify mature, correctly processed snoRNA expression. 
To provide orthogonal validation of the snoRNA expression data, we used 
commercially available reagents to perform quantitative reverse transcription PCR (RT-
qPCR) on a set of 9 snoRNAs with a wide range of expression across 11 primary AML 
samples.  Although some variability was observed, a significant correlation between 
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snoRNA expression determined by small RNA Seq and RT-qPCR was observed (R2 = 
0.5002; P < .0001; Figure 2.2). 
To determine whether our sequencing approach identified any novel RNA species, 
we formed read clusters by merging over-lapping reads and compared them with the RNA 
annotations as described above.  The intersection of read cluster coordinates with our 
sncRNA annotation set demonstrated that a number of them did not overlap with known 
annotations and could therefore represent novel RNA species.  The genomic regions 
spanned by these clusters were then analyzed for features of snoRNAs, including the 
presence of conserved sequence motifs and secondary structure.  Eight putative novel 
snoRNAs were identified, including 5 in the SNORA family and 3 in the SNORD family. 
One of the putative SNORDs lacked sequence complementarity to rRNAs or snRNAs and 
was therefore classified as an orphan snoRNA (Table 2.4).  There was some degree of 
overlap (≤50%) with annotated species, but our analysis supports the characterization of 
these snoRNAs as putatively novel. 
 
Developmental- and lineage-specific expression of snoRNAs in human 
hematopoiesis 
Because snoRNAs were the most abundant sncRNA detected, we focused our analysis 
on these RNA species.  We first performed unsupervised hierarchical clustering of 
annotated snoRNAs with a normalized expression of >5 RPM (N = 378) to determine 
whether expression of snoRNAs is developmentally regulated during hematopoiesis.  
This demonstrated that snoRNAs exhibit lineage- and developmentally restricted 
expression patterns (Figure 2.3).  The most striking examples were orphan snoRNAs 
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contained in the imprinted DLK-DIO3 and SNURF/SNRPN loci.  The DLK-DIO3 locus 
contained a large number of maternally expressed ncRNAs, including 41 snoRNAs, 11 
lncRNAs, and 53 miRNAs (Figure 2.4A).  Expression of snoRNAs in this locus was 
highest in CD34 cells and rapidly decreased with granulocytic differentiation, becoming 
nearly undetectable in mature neutrophils (Figure 2.4B).  Expression of these snoRNAs 
was also markedly reduced in B cells and T cells.  Expression of snoRNAs in the 
SNURF/SNRPN locus showed a similar, but distinct, pattern of snoRNA expression.  This 
locus contained 82 paternally expressed snoRNAs that were expressed at a high level in 
CD34 cells and rapidly downregulated during granulocytic differentiation (Figure 2.4C). 
However, in contrast to the DLK-DIO3 locus snoRNAs, expression of these snoRNAs 
remained high in B and T cells (Figure 2.4D). 
 
Expression of a subset of snoRNAs is decreased in AML 
We next compared snoRNA expression in 33 de novo AML samples with normal CD34 
cells.  Analysis of expression across all annotated snoRNA species (N = 364) via 
unsupervised hierarchical clustering demonstrated that AMLs had distinct snoRNA 
expression patterns from normal CD34 cells (Figure 2.5A).  We required a mean 
normalized expression of ≥5 counts across any AML and healthy donor samples to be 
considered for analysis.  Differential expression analysis identified 102 snoRNAs that 
were differentially expressed (adjusted P ≤0.05; absolute log2-fold change >1) (Table 2.5), 
all of which had decreased expression in the AML samples (Figure 2.5B).  By comparison, 
24 differentially expressed miRNAs were identified in a similar analysis using the same 
samples, which included 17 with increased expression in AML vs 7 that were decreased 
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(Figure 2.5C).  Although differentially expressed snoRNAs in AML spanned all RNA 
species, a disproportionate number of box C/D snoRNAs were observed (69 of 102, 
67.65%; Figure 2.5D), with 37 located in the DLK-DIO3 or SNURF- SNRPN loci.  There 
were 66 (64.71%) orphan snoRNAs with representation from all snoRNA classes. Of note, 
differential expression of snoRNAs that are known to play key roles in splicing as well as 
the modification of the peptidyl transferase center (PTC) and the intersubunit bridge (ISB) 
during ribosomal biogenesis was observed (Table 2.5).  For example, expression of 
SNORA21 and -36C, which target crucial nucleotides in the PTC and ISB, respectively, 
were decreased 2.69- and 2.56-fold, respectively, in AML compared with CD34 cells, and 
expression of SCARNA15, which targets a key nucleotide in the U2 spliceosomal RNA, 
was decreased 2.81-fold. 
 
Somatic mutation of snoRNAs is uncommon in AML 
Whole-genome sequencing data were available for 14 of the 33 analyzed cases in this 
study.  No somatic single nucleotide variants or small indels were detected in the snoRNA 
genes.  In addition, for those snoRNAs located in a host gene, no recurrent indels in the 
introns harboring the snoRNA or mutations in splice donor sites for that intron were 
identified.  We expanded this analysis to an additional 35 AML cases with whole-genome 
sequencing data available from The Cancer Genome Atlas275. Again, no somatic single 
nucleotide variants or small indels were detected in snoRNA genes, suggesting that 
genetic alterations in snoRNAs are uncommon in AML with normal cytogenetics and are 
not the cause of their differential expression in this disease. 
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There is minimal correlation between host gene and snoRNA expression 
Because many snoRNAs are located in the introns of host genes,74 we next asked 
whether variation in snoRNA expression may be explained by differences in expression 
and/or processing of these host genes.  We limited our analysis to the AML cases, where 
matching small RNA and total RNA-seq data were available.  For most snoRNAs, there 
was minimal correlation between host gene and corresponding snoRNA expression, as 
illustrated by host gene RPL7A and its corresponding snoRNAs (Figure 2.6A).  Across all 
1379 snoRNAs contained in host genes, the average coefficient of determination (R2) 
was 0.037 ± 0.102 (Figure 2.6B).  Multiple snoRNAs are often located within different 
introns of a single host gene, as shown for the C19orf48 gene (Figure 2.6C).  If host gene 
expression is the primary determinant of snoRNA expression, then expression of each 
snoRNA located in a given multihost gene should be similar.  However, we observed 
marked variability in the expression of snoRNAs contained within a single gene.  For 
example, expression of the 3 snoRNAs hosted by C19orf48 varied by >32-fold (Figure 
2.6D).  Indeed, marked variability in the expression of snoRNAs contained within the 
same host gene was observed in the majority of cases (Figure 2.6E).  These data show 
that host gene expression is not the primary determinant of snoRNA expression in AML. 
 
Alternative splicing of host genes is not the primary determinant of snoRNA 
expression 
Mature snoRNAs are processed from excised introns after splicing of the host gene.  
Thus, we next asked whether alternative splicing of host genes is a major determinant of 
snoRNA expression.  We assessed RNA splicing by measuring junction reads, as 
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previously described276.  For example, the host gene C19orf48 has 10 predicted splice 
events that involve introns containing embedded snoRNAs (Figure 2.7A).   Expression of 
junction reads corresponding to each splice event showed minimal correlation with 
expression of the relevant snoRNA (Figure 2.7B-K).   This analysis was extended to look 
at snoRNA expression and encompassing junction expression across 858 snoRNAs 
spanning 1616 junctions (Figure 2.7L).  For most cases, junction reads correlated 
minimally with snoRNA expression. Collectively, these data show that alternative splicing 































The expression of snoRNAs has traditionally been determined by high-throughput 
techniques that rely on hybridization-based methods, such as microarray analysis or by 
standard RNA-seq technologies97-99.  Microarrays for snoRNAs are unable to effectively 
capture novel sequences or resolve the expression of snoRNAs in families with highly 
homologous members100.   Standard RNA-seq is generally limited to RNA species >200 
nucleotides in length, and thus does not reliably detect most sncRNAs, including 
snoRNAs. In this study, we optimized both library preparation and bioinformatic analysis 
to address these challenges, which resulted in improved sensitivity for detecting novel 
sncRNAs, more accurate expression levels of annotated species, and efficient resolution 
of closely related snoRNA species, such as those in the DLK-DIO3 and SNURF-SNRPN 
loci. In addition, for those snoRNAs embedded in host genes, this approach can 
distinguish between host gene primary transcripts and mature, fully processed snoRNAs. 
The best method to normalize small RNA-seq expression data is uncertain.  For 
miRNAs, several studies have compared normalization methods, suggesting that the 
upper quartile, median, the DESeq normalization offered in the DESeq Bioconductor 
package, and the trimmed mean of M values offered in the edgeR Bioconductor package 
may be superior to the RPM normalization method277-279. In the absence of a “gold 
standard” for snoRNA expression, a rigorous comparison of normalization strategies of 
our small RNA-seq snoRNA expression data was not possible.  Thus, in this study, we 
normalized our small RNA-seq data with the widely used RPM method. 
To our knowledge, this is the first study to comprehensively analyze snoRNA 
expression in human hematopoiesis.  snoRNAs are the most highly expressed sncRNAs 
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in all of the hematopoietic cell populations tested. Although snoRNAs have been 
considered to be housekeeping genes,280 we identified a subset of snoRNAs that exhibit 
marked differential expression in a lineage- and development-specific pattern.  This is 
particularly true for orphan snoRNAs contained in the imprinted DLK-DIO3 and 
SNURF/SNRPN loci.  The DLK-DIO3 locus contains 47 orphan CD box snoRNAs that 
are highly expressed in CD34 cells and downregulated during myeloid or lymphoid 
differentiation.  This observation is consistent with previous reports showing high 
hematopoietic stem/progenitor expression of lncRNAs281 and miRNAs282 that are 
contained in the DLK-DIO3 locus.  The SNURF/SNRPN locus contains 2 large orphan 
CD box snoRNA clusters, SNORD115 and SNORD116, that are expressed highly in 
CD34 cells and downregulated during myeloid differentiation.  Loss of SNORD116 in the 
SNURF/ SNRPN locus is thought to be key to the pathogenesis of Prader-Willi syndrome, 
a genetic disorder characterized by obesity and developmental delay283,284.  Of note, 
SNORD115 has been shown to promote alternative splicing of the serotonin receptor 
2C72.  The contribution of the DLK-DIO3 and SNURF/SNRPN loci to hematopoietic 
stem/progenitor function is un-known, although it is interesting to note that expression of 
ncRNAs from the DLK-DIO3 locus correlates with pluripotency in both embryonic and 
inducible pluripotent stem cells285. 
We observed no recurring mutations of snoRNA genes in our cohort of 
cytogenetically normal AML, suggesting that genetic alterations that specifically target 
snoRNAs in AML are uncommon.  A previous study reported that snoRNAs are globally 
suppressed in AML relative to CD34 cells from normal hematopoietic stem/progenitors99. 
Although we also observed a trend toward decreased expression in AML, this was limited 
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to a small subset of snoRNAs (102 of 364, 28%).  The reasons for this discrepancy are 
not certain, but the previous study primarily used a microarray approach to assess 
expression of a more limited set of snoRNAs.  Of note, of the 102 snoRNAs with 
significantly reduced expression in AML, 37 are located in the DLK-DIO3 or SNURF-
SNRPN loci.  Because expression of these snoRNAs is suppressed during normal 
myeloid differentiation, it is possible that their decrease in AML reflects normal 
differentiation along the myeloid lineage.   This is in sharp contrast to previous studies 
showing marked increased expression of DLK-DIO3 snoRNAs in acute promyelocytic 
leukemia97,99,242. Of note, Valleron et al., showed that enforced expression of SNORD114-
1, which is contained in the DLK1-DIO3 locus, promotes cell growth in vitro, possibly by 
targeting the Rb pathway.99 
We observed significant differential expression of snoRNAs that mediate 
pseudouridylation or 2’-O methylation of key sites in rRNA.  Decreased expression of 
snoRNAs that target modifications of the PTC and ISB regions of the 60S ribosome was 
observed in AML patients vs normal hematopoietic stem/progenitors.   The PTC is the 
catalytic site where peptide bonds are made during protein elongation and peptidyl-tRNAs 
are hydrolyzed during the termination of protein synthesis286.  The ISB forms multiple 
interactions between the ribosomal subunits, which maintain ribosome stability and 
modulate dynamics that are critical for translation, such as that between the tRNA and 
mRNA287.  Studies in yeast suggest that, although loss of pseudouridylation or 2’-O 
methylation at individual rRNA sites has only subtle effects on activity, loss at multiple 
sites is synergistic, resulting in reading frame changes, increased stop - codon read-
through, and altered tRNA selection118,128,288. We also identified several snoRNAs 
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responsible for the pseudouridylation of snRNAs in regions critical for splicing.  For 
example, scaRNA15, whose expression is reduced 2.81-fold in AML, targets the branch 
site recognition region of U2 snRNA.  Studies in HeLa cells289 and yeast162 show that 
pseudouridylation at this site is required for the formation of early spliceosomal complexes 
and the catalytic phase of pre-mRNA splicing.  Further study is needed to determine 
whether the observed decreases in snoRNA expression in AML are sufficient to induce 
biologically meaningful differences in translation or splicing. 
The mechanisms regulating snoRNA expression are not well defined.  Most 
snoRNAs and scaRNAs are embedded in the introns of host genes that produce proteins 
involved in nucleolar function, ribosome structure, or protein synthesis,3 providing a 
potential mechanism for the coordinated expression of snoRNAs and proteins targeting 
common pathways.  Interestingly, we observed that in AML, snoRNA expression 
correlates minimally with host gene expression.   Recent studies in yeast and human 
brain samples have reported a similar uncoupling of host gene and snoRNA 
expression290-292. Indeed, we even observed striking variability in the expression of 
snoRNAs contained in the same host gene.  Mature snoRNAs are produced from host 
genes by exonucleolytic processing of the debranched intron after splicing293,294. A recent 
study suggested that alternative splicing of host genes contributes to the regulation of 
snoRNA expression and accounts, in part, for the variability in the expression of snoRNAs 
contained with the same host gene295.  However, in AML, snoRNA expression and 
alternative splicing correlate minimally.  Thus, in AML, other mechanisms besides host 
gene expression or splicing are contributing to mature snoRNA expression.  This may 
include alterations in snoRNA processing, secondary snoRNA structure stability, 
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maturation, trans-acting protein accumulation factors, and intranuclear trafficking of the 
maturing snoRNPs to the nucleolus or Cajal body296.  Of note, many snoRNA host genes 
contain a characteristic terminal oligopyrimidine track in their 59-untranslated region that 
has been shown to modulate the differential production of mRNA vs snoRNAs from that 
host gene297,298.   Given the critical role of snoRNAs in translation, the contribution of 
these various elements to the regulation of snoRNA expression warrants further study. 
As outlined, array-based and qPCR-based approaches do not distinguish between 
mature snoRNAs and primary mRNA transcripts containing unprocessed snoRNAs. 
Without robust orthogonal validation technologies for generating gold standard 
expression values, optimal statistical procedures for expression normalization from count-
based sequence data have not been established for snoRNAs.  This contrasts with 
miRNA sequencing data, for which qPCR provides robust orthogonal validation that has 
made it possible to evaluate and optimize expression normalization methods278.  In the 
absence of a consensus approach for snoRNA data, we used the total count method, 
which involves normalization of the read count for each snoRNA species for the total 
number of counts obtained for each experiment.  Additional studies will be needed to 
determine the optimal normalization procedures for sequence data from this intermediate-
sized RNA species. 
In summary, we developed a small RNA-seq pipeline to quantify snoRNA and 
other sncRNA expression.  We showed that a subset of snoRNAs are regulated in 
lineage- and development-specific expression. Although genetic alterations that 
specifically target snoRNA genes in AML appear to be uncommon, a subset of snoRNAs 
are differentially expressed.  The contribution of these differentially expressed snoRNAs 
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Figure 2.1 Small RNA-Seq pipeline. (A) Schematic representation of the small 
RNA-seq pipeline. Sequence reads were aligned to the GENCODE version 19, 
miRBase version 21, and human snoRNAome, and reads corresponding to 
annotated sncRNAs were quantified (left pathway). Alternatively, aligned 
sequence reads were organized into genomic clusters; a total of 111 
unannotated clusters were identified, of which 8 were classified as novel 
snoRNAs (right pathway). (B) Graph showing the distribution of annotation 
biotypes in GENCODE version 19 for mapped reads from all samples. The 
percentage of all mapped reads (mapping quality >0) is shown on the y-axis, 
and the annotated species is shown on the x-axis. Miscellaneous (Misc) 
snoRNAs include rRNAs, other species include unprocessed pseudogenes, 
immunoglobulin genes, T-cell receptor genes, sense introns, antisense 
transcripts, sense overlapping transcripts, retained introns, and processed 
transcripts. Protein-coding genes include nonsense mediated decay, and 
nonstop decay biotypes. (C) Integrated Genome Viewer browser view of 
SNORA64, which is embedded in an intron of the coding gene RPS2. The top 
that standard transcriptome sequencing cannot reliably distinguish
unspliced primary host gene RNA from correctly processed
snoRNA. Typical r sults are shown for SNORA64, which is located
in the intron of its host gene, RP32 (Figure 1C). Whereas sequence
reads corresponding to mature SNOR64 were readily identified
using our pipeline, only low-level reads that span the entire intron
of RP32 were detected using total RNA-seq. Accordingly, the
correlation of snoRNAs quantified using these 2 RNA-seq pipelines
was poor (Figure 1D). These data demonstrate the superiority of our
small seque cing pipeline to quantify mature, correctly process
snoRNA expression.
To provide orthogonal validation of the snoRNA expression data, we
used commercially available reagents to perform quantitative reverse
transcription PCR (RT-qPCR) on a set of 9 snoRNAs with a wide
range of expression across 11 primary AML samples. Although some
variability was observed, a significant correlation between snoRNA
expression determined by small RNA Seq and RT-qPCR was
observed (R2 5 0.5002; P , .0001; supplemental Figure 1).
To determine whether our sequencing approach identified any
novel RNA species, we formed read clusters by merging over-
lapping reads and compared them with the RNA annotations as
described above. The intersection of read cluster coordinates with
our sncRNA annotation set demonstrated that a number of them did
not overlap with known annotations, and could therefore represent
novel RNA species. The genomic regions spanned by these
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Figure 1. Small RNA-Seq pipeline. (A) Schematic representation of the small RNA-seq pipeline. Sequence reads were aligned to the GENCODE version 19, miRBase
version 21, and human snoRNAome, and reads corresponding to annotated sncRNAs were quantified (left pathway). Alternatively, aligned sequence reads were organized
into genomic clusters; a total of 111 unannotated clusters were identified, of which 8 were classified as novel snoRNAs (right pathway). (B) Graph showing the distribution of
annotation biotypes in GENCODE version 19 for mapped reads from all samples. The percentage of all mapped reads (mapping quality .0) is shown on the y-axis, and the
annotated species is shown on the x-axis. Miscellaneous (Misc) snoRNAs include rRNAs, other species include unprocessed pseudogenes, immunoglobulin genes, T-cell
receptor genes, sense introns, antisense transcripts, sense overlapping transcripts, retained introns, and processed transcripts. Protein-coding genes include nonsense
mediated decay, and nonstop decay biotypes. (C) Integrated Genome Viewer browser view of SNORA64, which is embedded in an intron of the coding gene RPS2. The top
panel shows the alignment of reads generated using total RNA-seq. The middle panel shows the alignment of reads from a small RNA-seq library produced from the same
sample. The genomic boundaries of SNORA64 and exons 4 and 5 of host gene RPS2 are shown in the bottom panel. (D) Representative scatter plot showing log-transformed
normalized read counts of annotated snoRNAs for a CD34 sample analyzed using total RNA-seq (y-axis) or our small RNA-seq pipeline (x-axis).
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panel shows the alignment of reads generated using total RNA-seq. The middle 
panel shows the alignment of reads from a small RNA-seq library produced from 
the same sample. The genomic boundaries of SNORA64 and exons 4 and 5 of 
host gene RPS2 are shown in the bottom panel. (D) Representative scatter plot 
showing log-transformed normalized read counts of annotated snoRNAs for a 
















































Figure 2.3 Unsupervised hierarchical clustering of snoRNA expression. Small RNA-
seq was performed on the indicated sorted hematopoietic cell populations obtained from 
4-6 normal hematopoietic stem/progenitors. snoRNA expression (z-scored log2 RPM) is 
shown, with red indicating high expression, and green indicating low expression. Each 







explained by differences in expression and/or processing of these
host genes. We limited our analysis to the AML cases, where
matching small RNA and total RNA-seq data were available. For most
snoRNAs, there was minimal correlation between host gene and
corresponding snoRNA expression, as illustrated by host gene
RPL7A and its corresponding snoRNAs (Figure 5A). Across all 1379
snoRNAs contained in host genes, the average coefficient of
determination (R2) was 0.037 6 0.102 (Figure 5B). Multiple
snoRNAs are often located within different introns of a single host
gene, as shown for the C19orf48 gene (Figure 5C). If host gene
expression is the primary determinant of snoRNA expression, then
expression of each snoRNA located in a given multihost gene should
be similar. However, we observed marked variability in the expression
of snoRNAs contained within a single gene. For example, expression
of the 3 snoRNAs hosted by C19orf48 varied by .32-fold
(Figure 5D). Indeed, marked variability in the expression of snoRNAs
contained within the same host gene was observed in the majority of
cases (Figure 5E). These data show that host gene expression is not
the primary determinant of snoRNA expression in AML.
Alternative splicing of host genes is not the primary
determinant of snoRNA expression
Mature snoRNAs are processed from excised introns after splicing of
the host gene. Thus, we next asked whether alternative splicing of host
genes is a major determinant of snoRNA expression. We assessed
RNA splicing by measuring junction reads, as previously described.37
For example, the host gene C19orf48 has 10 predicted splice events
that involve introns containing embedded snoRNAs (Figure 6A).
Expression of junction reads corresponding to each splice event
showed minimal correlation with expression of the relevant snoRNA
(Figure 6B-K). This analysis was extended to look at snoRNA
expression and encompassing junction expression across 858
snoRNAs spanning 1616 junctions (Figure 6L). For most cases,
junction reads correlated minimally with snoRNA expression. Collec-
tively, these data show that alternative splicing of host genes is unlikely
to be the primary determinant of snoRNA expression.
Discussion
The expression of snoRNAs has traditionally been determined by
high-throughput techniques that rely on hybridization-based meth-
ods, such as microarray analysis or by standard RNA-seq
technologies.12-14 Microarrays for snoRNAs are unable to effec-
tively capture novel sequences or resolve the expression of
snoRNAs in families with highly homologous members.38 Standard
RNA-seq is generally limited to RNA species .200 nucleotides in
length, and thus does not reliably detect most sncRNAs, including
snoRNAs. In this study, we optimized both library preparation and
bioinformatic analysis to address these challenges, which resulted
in improved sensitivity for detecting novel sncRNAs, more accurate
expression levels of annotated species, and efficient resolution of
closely related snoRNA species, such as those in the DLK-DIO3
and SNURF-SNRPN loci. In addition, for those snoRNAs embed-
ded in host genes, this approach can distinguish between host

















Figure 2. Unsupervised hierarchical clustering of snoRNA expression. Small RNA-seq was performed on the indicated sorted hematopoietic cell populations obtained
from 4-6 normal hematopoietic stem/progenitors. snoRNA expression (z-scored log2 RPM) is shown, with red indicating high expression, and green indicating low expression.
Each column represents a unique snoRNA, and each row represents a sample.
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Figure 2.4. Expression of snoRNAs in the DLK-DIO3 and SNURF/SNRPN loci. (A) 
Organization of the DLK-DIO3 locus. Maternally expressed genes (open boxes) and 
paternally expressed genes (filled boxes) are shown. The miRNA cluster contains 54 
miRNAs. (B) Normalized read counts for SNORD113-6 are shown; its expression is 
representative of other SNORDs in this locus. Significance was determined by 1-way 
ANOVA followed by Tukey multiple comparisons test. (C) Organization of the human 
SNURF-SNRPN locus (drawing is not to scale). Paternally expressed genes, including 
SNORDs, are shown as n, and maternally expressed genes are shown as N. (D) 
Normalized read counts for SNORD116-1, representative of SNORDs in the SNURF-
SNRPN locus, are shown. ****P < .0001. ns, not significant.  
 
 
The best method to normalize small RNA-seq expression data is
uncertain. For miRNAs, several studies have compared normalization
methods, suggesting that the upper quartile, median, the DESeq
normalization offered in the DESeq Bioconductor package, and the
trimmedmean ofM values offered in the edgeRBioconductor package
may be superior to the RPM normalization method.39-41 In the absence
of a “gold standard” for snoRNA expression, a rigorous comparison of
normalization strategies of our small RNA-seq snoRNA expression data
was not possible. Thus, in this study, we normalized our small RNA-seq
data with the widely used RPM method.
To our knowledge is the first study to comprehensively analyze
snoRNA expression in human hematopoiesis. snoRNAs are the most
highly expressed sncRNAs in all of the hematopoietic cell populations
tested. Although snoRNAs have been considered to be housekeep-
ing genes,42 we identified a subset of snoRNAs that exhibit marked
differential expression in a lineage- and development-specific pattern.
This is particularly true for orphan snoRNAs contained in the
imprinted DLK-DIO3 and SNURF/SNRPN loci. The DLK-DIO3
locus contains 47 orphan CD box snoRNAs that are highly
expressed in CD34 cells and downregulated during myeloid or
lymphoid differentiation. This observation is consistent with
previous reports showing high hematopoietic stem/progenitor
expression of lncRNAs43 and miRNAs44 that are contained in the
DLK-DIO3 locus. The SNURF/SNRPN locus contains 2 large
orphan CD box snoRNA clusters, SNORD115 and SNORD116,
that are expressed highly in CD34 cells and downregulated during
myeloid differentiation. Loss of SNORD116 in the SNURF/
SNRPN locus is thought to be key to the pathogenesis of
Prader-Willi syndrome, a genetic disorder characterized by
obesity and developmental delay.45,46 Of note, SNORD115 has
been shown to promote alternative splicing of the serotonin
receptor 2C.47 The contribution of the DLK-DIO3 and SNURF/
SNRPN loci to hematopoietic stem/progenitor function is un-
known, although it is interesting to note that expression of ncRNAs
from the DLK-DIO3 locus correlates with pluripotency in both
































































































































Figure 3. Expression of snoRNAs in the DLK-DIO3 and SNURF/SNRPN loci. (A) Organization of the DLK-DIO3 locus. Maternally expressed genes (open boxes)
and paternally expressed genes (filled boxes) are shown. The miRNA cluster contains 54 miRNAs. (B) Normalized read counts for SNORD113-6 are shown;
its expression is representative of other SNORDs in this locus. Significance was determined by 1-way ANOVA followed by Tukey multiple comparisons test.
(C) Organization of the human SNURF-SNRPN locus (drawing is not to scale). Paternally expressed genes, including SNORDs, are shown as n, and maternally
expressed genes are shown as N. (D) Normalized read counts for SNORD116-1, representative of SNORDs in the SNURF-SNRPN locus, are shown.
****P , .0001. ns, not significant.
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Figure 2.5. Differentially expressed snoRNAs. (A) Unsupervised hierarchical 
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Figure 4. Differentially expressed snoRNAs. (A) Unsupervised hierarchical clustering of snoRNA expression in AML and CD34 from healthy adult donors based on z
scores, with red indicating high expression, and green indicating low expression. Each column represents a specific snoRNA, and each row represents an individual sample.
(B-C) Volcano plot illustrating significant differentially expressed snoRNAs (B) and miRNAs (C). The fold change difference in RNA expression between AML and normal CD34
samples is plotted on the x-axis, and P value significance is plotted on the y-axis. The horizontal line on the plot represents the a-level used for this analysis (0.05). Vertical lines
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z scores, with red indicating high expression, and green indicating low expression. Each 
column represents a specific snoRNA, and each row represents an individual sample. (B-
C) Volcano plot illustrating significant differentially expressed snoRNAs (B) and miRNAs 
(C) The fold change difference in RNA expression between AML and normal CD34 
samples is plotted on the x-axis, and P value significance is plotted on the y-axis. The 
horizontal line on the plot represents the P-level used for this analysis (0.05). Vertical 
lines represent the threshold for the log2 fold change (equivalent to a twofold difference). 
The y-axis reflects the -log10 (q value–corrected P value). Green and red colored dots 
represent snoRNAs showing significantly increased or decreased expression in AML, 
respectively. (D) Distribution of differentially expressed snoRNAs across snoRNA 























Figure 2.6. Correlation between host gene and snoRNAs expression. (A) 
Representative plot showing the correlation between the normalized expression of the 
host gene RPL7A and its encoded SNORD36B in AML. (B) Summary scatter plot showing 
the coefficient of determination (R 2) of all host gene/snoRNAs pairs (N = 1379, mean ± 
SEM = 0.037 6 ± 0.102). (C) Organization of the human gene C19orf48 gene (drawing 
not to scale); exons are shown as a box and SNORD88B, -88A and -88C are shown in 
green, blue-, or red-filled boxes, respectively. (D) Log-transformed normalized read 
counts in AML. Significance was determined by 1-way ANOVA followed by Tukey multiple 
comparisons test. (E) Plot showing the log-transformed median expression values for all 
expressed snoRNAs in a multi-host gene (N = 130). Each line represents a distinct multi-
host gene.  
We observed no recurring mutations of snoRNA genes in our cohort
of cytogenetically normal AML, suggesting that genetic alterations
that specifically target snoRNAs in AML are uncommon. A previous
study reported that snoRNAs are globally suppressed in AML relative
to CD34 cells from normal hematopoietic stem/progenitors.14
Although we also observed a trend toward decreased xpression
in AML, this was limited to a small subset of snoRNAs (102 of 364,
28%). The reasons for this discrepancy are not certain, but the
previous study primarily used a microarray approach to assess
expression of a more limited set of snoRNAs. Of note, of the 102
snoRNAs with significantly reduced expression in AML, 37 are
located in the DLK-DIO3 or SNURF-SNRPN loci. Because
expression of these snoRNAs is suppressed during normal myeloid
differentiation, it is possible that their decrease in AML reflects normal
differentiation along the myeloid lineage. This is in sharp contrast to
previous studies showing marked increased expression ofDLK-DIO3
snoRNAs in acute promyelocytic leukemia.12-14 Of note, Valleron et al
showed that enforced expression of SNORD114-1, which is
Figure 4. (continued) represent the threshold for the log2 fold change (equivalent to a twofold difference). The y-axis reflects the 2log10 (q value–corrected P value). Green
and red colored dots represent snoRNAs showing significantly increased or decreased expression in AML, respectively. (D) Distribution of differentially expressed snoRNAs
















































































Figure 5. Correlation between host gene and snoRNAs expression. (A) Representative plot showing the correlation between the normalized expression of the host
gene RPL7A and its encoded SNORD36B in AML. (B) Summary scatter plot showing the coefficient of determination (R2) of all host gene/snoRNAs pairs (N 5 1379, mean 6 SEM
5 0.037 6 0.102). (C) Organization of the human gene C19orf48 gene (drawing not to scale); exons are shown as n and SNORD88B, 288A and 288C are shown in green-,
blue-, or red-filled boxes, respectively. (D) Log-transformed normalized read counts in AML. Significance was determined by 1-way ANOVA followed by Tukey multiple comparisons test.
(E) Plot showing the log-transformed median expression values for all expressed snoRNAs in a multihost gene (N 5 130). Each line represents a distinct multihost gene.
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Figure 2.7. Correlation of host gene splicing to snoRNA expression. (A) Schematic 
















































































































































































































































Figure 6. Correlation of host gene splicing to snoRNA expression. (A) Schematic of all splice junctions for C19orf48. Coding exons are shown as n and embedded
snoRNAs as color-filled boxes. Each numbered line represents a different splice event. Drawing not to scale. (B-K) RNA splicing was assessed by quantifying each of the
junction reads (splice 1-10). Shown are scatter plots showing normalized junction reads (reads per million) vs snoRNA expression (reads per million). (L) Scatter plot
showing R2 values (mean 6 SEM 5 0.041 6 0.093) between snoRNA expression and host gene splicing (total of 1616 junction reads).
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snoRNAs as color-filled boxes. Each numbered line represents a different splice event. 
Drawing not to scale. (B-K) RNA splicing was assessed by quantifying each of the junction 
reads (splice 1-10). Shown are scatter plots showing normalized junction reads (reads 
per million) vs snoRNA expression (reads per million). (L) Scatter plot showing R2 values 
(mean ± SEM = 0.041 ± 0.093) between snoRNA expression and host gene splicing (total 
























































AML is a complex and dynamic disease with a varied driver landscape providing discrete 
paths to leukemogenesis, disease pathophysiology, progression and recurrence275,299,300.  
This landscape includes fusion genes, and mutations in RNA-splicing regulators. snoRNA 
expression in these subtypes of AML is not well characterized.  In the previous chapter, 
we looked at snoRNA expression in AML patient samples driven primarily by recurrent 
mutations in NPM1, FLT3, DNMT3A, IDH1/2, NRAS or KRAS, CEBPA, TET2, WT1, and 
PTPN11192.  Here we expand on this work by looking at AML samples characterized by 
fusions, and mutations in splicing factors. 
Fifteen percent of all AML cases and possibly up to 40% of M2 AML harbor the 
t(8;21)(q22;q22) translocation that leads to the RUNX1-RUNX1T1 fusion oncoprotein 
(also known as AML1-ETO) (Figure 3.1).   This oncoprotein includes the N-terminal DNA-
binding domain of RUNX1, a DNA binding transcription factor essential for definitive 
hematopoiesis, and frequently mutated in de novo and therapy related AML, MDS, 
chronic myelomonocytic leukemia and acute lymphocytic leukemia301,302.   A recent report 
suggested that the AML1-ETO oncoprotein alters ribosomal biogenesis by increasing 
expression of C/D box snoRNAs102.  Increased expression of C/D box snoRNAs also was 
observed in cells expressing MLL-AF9.   The authors propose that upregulation of C/D 
box snoRNA expression, by increasing 2′-O-methylation of ribosomal RNA, plays a key 
role in the induction of AML by AML1-ETO and possibly MLL translocations.  However, 
microarrays were used to profile snoRNAs in this study, which may not be accurate, since 
they detect both the precursor and mature snoRNAs192,303.   Moreover, it is not clear 
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whether other core binding factor AMLs, such as (16)/t(16:16) AML that express the 
CBFB-MYH11 fusion gene, have altered snoRNA expression.    
The t(15;17) translocation in acute promyelocytic leukemia (APML) generates a 
PML/RAR-α oncoprotein (Figure 3.1).   Previous studies have reported marked increased 
expression of DLK-DIO3 snoRNAs in APML97,99,242.  The imprinted DLK-DIO3 locus 
contains a large number of maternally expressed small non-coding RNAs, including 41 
snoRNAs and 54 miRNAs. DLK-DIO3 snoRNAs are highly expressed in primitive human 
CD34+ cells, and their expression is rapidly silenced during hematopoietic 
differentiation192.  The function of DLK-DIO3 snoRNAs is unknown.  They are orphan CD-
box snoRNAs that are computationally predicted, in one study, to target rRNA241.  
Whether other snoRNAs are dysregulated in APML is currently unknown.   
Mutations in spliceosome genes are found in approximately 50% of MDS.   The 
most commonly mutated spliceosome genes are SF3B1, SRSF2, and U2AF1.  
Mutations in each of these genes has been shown to result in altered splicing, although 
the specific genes that are affected are mostly distinct.   This is relevant to snoRNAs, 
since the majority of snoRNAs are located in the introns of host genes and snoRNA 
biogenesis is dependent on splicing.  Specifically, snoRNAs are processed 
exonucleolytically from spliced and debranched introns and released by endonucleolytic 
cleavages under the action of splicing factors74.  Thus, we hypothesized that snoRNA 
biogenesis may be altered in myeloid malignancies carrying spliceosome mutations. 
 In this study, we sequenced the small RNA transcriptome of the following 
myeloid malignancies: core binding factor AML, PML-RARa AML, spliceosome gene 
mutated AML, and AML carrying an MLL rearrangement.   We show that, in general, 
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snoRNA expression is decreased compared to CD34+ cells from healthy donors.  
Specific patterns of snoRNA expression were observed in each genetic AML subtype.  
However, we were not able to confirm an increase in C/D box snoRNA expression in 
core binding factor AML.  Studies to assess the impact of splicing alterations on 
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MATERIALS AND METHODS 
We acquired AML samples characterized by fusions, and mutations in splicing factors as 
well as CD34 samples from healthy donors.  The characteristics of these patients are fully 
described in Table 3.1, Figures 3.1-2 and elsewhere304.  All patients in this study were 
enrolled in a single-institution tissue-banking protocol approved by the human studies 
committee at Washington University School of Medicine. Written informed consent for 
genome sequencing was obtained from all study participants.  
All samples were interrogated to assess the snoRNA differential expression.   
Small RNA library construction was performed as previously described192.  Sequencing 
was performed on an Illumina NextSeq 500 on a high output flowcell, targeting 400 million 
reads as a 2x150 configuration by the DNA Sequencing Innovation Lab at the Center for 
Genome Sciences and Systems Biology, Washington University, St. Louis, MO.  The 
bioinformatic analysis pipeline has been previously described192.  Differential expression 
analysis was carried out using Partek Genomic Suite as previously described192.  
Statistical significance was determined using Prism 6.0 software (GraphPad). 
Unpaired t test, 2-way ANOVA, or ANOVA with Tukey’s Honest Significant Difference 
post hoc analysis was used to evaluate the significance of differences between multiple 











Distinct patterns of snoRNA expression are associated with genetic subtypes of AML. 
We sequenced the small RNA transcriptome of 12 AML cases with an MLL translocation, 
15 cases of core-binding factor AML, 16 AML cases with a spliceosome gene mutation, 
and 14 cases of APML (Table 3.1, Figures 3.1-2).  These data were compared to CD34 
cells isolated from 6 healthy donors.   
 Unsupervised hierarchical cluster analysis of expressed snoRNAs showed that 
differential snoRNA expression defined most of the AML subsets (Figure. 3.3).   The 
number of differentially expressed snoRNAs (compared to normal CD34 cells) for each 
AML subset is shown in Table 3.2.   For most of the AML subtypes, a similar pattern was 
observed, with decreased expression of C/D box snoRNAs representing the majority of 
differentially expressed snoRNAs (Table 3.2).   The exception is AML carrying the PML-
RAR oncogene, where increased expression of C/D box snoRNA was observed (see 
section on PML-RARa AML below).   
We next asked whether there were snoRNAs that showed differential gene 
expression across all or multiple AML subtypes.  The intersectionality of the differentially 
expressed snoRNAs revealed that there are 36 differentially expressed snoRNAs in 
common (Figure 3.4, Table 3.3).  Of these, 22 (77.8%) were C/D box snoRNAs with 8 
housed in the DLK-DIO3 locus.   Two of the snoRNAs (SNORD1A, and SNORA10) play 
a key role in the PTC modification and one (SNORD36C) is involved in modification of 
the ribosomal ISB.  
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Expression of snoRNAs from the imprinted DLK-DIO3 and SNURF-SNRPN loci is 
markedly increased in APML.   
The imprinted SNURF-SNRPN locus is the largest cluster of C/D box snoRNAs in the 
human genome.   It includes 24 members of the SNORD116 family, 47 copies of the 
SNORD115 family, along with SNORD107, SNORD164, SNORD109A, and 
SNORD109B (Figure 3.5A).   Expression of many of the snoRNAs in this locus were 
markedly decreased in APML compared to normal CD34 cells (Figure 3.5B).   For 
example, expression of SNORD116-14 was increased nearly 500-fold.   Additionally, 
expression of SNURF-SNRPN locus snoRNAs was decreased relative to CBF and MLL 
translocations and some samples with mutations in splicing factors.   The DLK-DIO3 
imprinted locus contains another large cluster of C/D box snoRNAs (Figure 3.6A).  
Consistent with prior studies, we observed a marked increase in expression of DLK-DIO3 
snoRNAs in APML (Figure 3.6B)97,99,242.   In contrast to APML, expression of snoRNAs in 
the DLK-DIO3 locus in other types of AML was decreased related to CD34 cells, 
consistent with our prior study192.   
 
C/D box snoRNAs expression in Core Binding Factor AML and AML carrying MLL 
translocations is not globally increased. 
A prior study reported that C/D box snoRNA expression was increased in AML with 
RUNX1-RUNX1T1 t(8;21) expressing the AML1-ETO oncogene102.  To confirm and 
extend this finding to other core binding factor AMLs, we analyzed 15 cases of CBF AML, 
including 10 cases with MYH11 (inv(16)/t(16;16)) and four cases with RUNX1-RUNX1T1 
(t(8;21)(q22;q22)).  Compared to normal CD34+ cells, a total of 109 differentially 
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expressed snoRNA were identified, with the majority being downregulated (Figure 3.7A).  
Limiting the analysis to C/D box snoRNAs, 67 differentially expressed snoRNAs were 
identified, of which only 6 were upregulated (Figure 3.7B).  To directly compare our results 
to that of Zhou and colleagues, we limited our analysis to the 4 four cases of AML with 
RUNX1-RUNX1T1.  A total of 50 differentially expressed C/D Box snoRNAs were 
identified, of which 5 were increased.  Indeed, only one of the C/D box snoRNAs 
(SNORD104) reported as overexpressed by Zhou et al showed a similar pattern in our 
cohort (Supplementary Table 3.1)102.  
 Zhou et al also reported that expression of MLL-AF9 resulted in increased C/D box 
snoRNA expression.   Thus, we also analyzed 11 cases of AML carrying translocations 
of MLL (Table 3.1).   A total of 84 differentially expressed snoRNAs were identified, 
including 44 C/D box snoRNAs with decreased expression versus just 6 C/D box 
snoRNAs with increased expression (Supplementary Table 3.2).   
 
Heterogeneity of snoRNA expression in AMLs with splicing factor mutations  
We next asked whether splicing changes present in AML carrying spliceosome mutations 
affected snoRNA expression.   A total of 16 AML cases were analyzed, including 11 with 
U2AF1 mutations, 3 with SRSF2 mutations, and 2 with SF3B1 mutations.   Comparing 
spliceosome gene-mutated AML as a group to normal CD34 cells, 107 differentially 
expressed snoRNAs were identified, with the majority (94%) showing decreased 
expression (Figure 3.8A, Supplementary Table 3.3).   This pattern is held true for each 
spliceosome gene mutation subtype (Figure 3.8B).  There is evidence that distinct splicing 
alterations are associated with the different spliceosome gene mutations.   However, 
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unsupervised hierarchal clustering showed no distinct patterns for AML carrying U2AF1, 
SRSF2, or SF3B1 mutations (Figure 3.9).   Indeed, little overlap was observed in the 
differentially expressed snoRNAs observed in AMLs carrying (Figure 3.10, Table 3.4).   Of 
note, AML with U2AF1 splicing factor mutations decreased expression had the most 
unique DE snoRNAs.   
         To look in more detail at the effect of host gene splicing to snoRNA expression, we 
performed deep RNA sequencing on a subset of the AML samples carrying spliceosome 
















AML is a complex disease driven by a variety of factors that culminate in a block to 
differentiation and a build-up of leukemic blasts.  Recently, there has been significant 
interest in snoRNAs and the role they play in AML.   Many of these studies rely on less 
than optimal hybridization approaches to quantify snoRNAs.  In the previous chapter, we 
reported on our development of optimal approaches for quantifying snoRNA.  In the 
current study, we build on that work by sequencing the small RNA transcriptome of 12 
AML cases with an MLL translocation, 15 cases of core-binding factor AML, 16 AML 
cases with a spliceosome gene mutation, and 14 cases of APML. 
We found that distinct patterns of snoRNA expression are associated with genetic 
subtypes of AML and that these patterns provide a signature to differentiate AML subtypes. 
This varied and specific expression contradicts earlier thinking that snoRNAs are simply 
housekeeping genes.   Intersecting the subsets of differentially expressed snoRNAs we found 
that a subset (36) were differentially expressed across all of the classes we interrogated. 
Whether these snoRNAs play a common role in maintaining the leukemic state is not clear and 
is worthy of further investigation.  Interestingly, 8 of the common orphan snoRNAs are in the 
DLK-DIO3 locus and as such they are overexpressed in APL samples and under expressed 
in all other AML relative to CD34, suggesting that they might have a functional relevance. 
Additionally, several of these snoRNAs modify targets in the PTC suggesting that translation 
might be commonly impacted in these AML subtypes. 
Recent work by Zhou et al., reported that CD box snoRNAs are overexpressed in 
AML-ETO samples and that this plays a critical role in leukemogenesis.  They point to 
C/D box snoRNA overexpression as a driver of leukemogenesis.   However, we were 
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unable to confirm these findings in 15 CBF AML samples, including 4 AML cases 
expressing AML-ETO.   These discrepant results may be secondary to the method used 
for snoRNA quantification.   Whereas we used our small RNA sequencing pipeline, Zhou 
et al., used microarrays, which may be less accurate.   Of note, Zhou and colleagues 
used RT-PCR to confirm overexpression of 9 C/D box snoRNAs in 4 AML-ETO AML 
samples.  However, expression of only one of these, SNORD104, was increased in our 
cohort.   
DLK-DIO3 snoRNA genes are tandemly repeated C/D snoRNAs located ∼25 kb 
downstream of Rtl1 and processed from a complex transcription unit mapping to 
the MEG8 gene239.  There have been numerous studies that used sub-optimal 
hybridization techniques to report on a DLK-DIO3 APML signature in which the snoRNAs 
(SNORD113-3, SNORD113-4, SNORD114-2 and SNORD114-3 ) are up-regulated 
relative to CD34 and NK AML97,99,242.   We report similar findings here and provide a 
complete picture of the APML snoRNA landscape for the first time.   
One area of significance is the SNURF/SNRPN locus which has a similar, but 
distinct, pattern of snoRNA expression.  This locus contained 82 paternally expressed 
snoRNAs localized in the Prader-Willi critical region on chromosome 1568.  This locus is 
one of the most complex transcriptional units in the human genome spanning more than 
460 kb and containing at least 148 exons. The locus harbors a bipartite imprinting center 
(IC) that silences most maternal genes of the Prader-Willi critical region68.  As we noted 
for all AML, the SNORD115 family is not expressed.  Here we report for the first-time 
suppressed expression of orphan SNORD116 snoRNAs in APML samples.  This is in 
contrast to the pattern observed for all other AMLs we have looked at.  Clearly the 
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imprinted loci are dysregulated in APL.  Further studies are needed to better understand 
the role of these orphan snoRNAs in this setting.  
A recent study looking at Prader-Willi syndrome (PWS), a developmental 
imprinting disorder, unexpectedly found substantial upregulation of virtually all maternally 
expressed genes (MEGs) in the imprinted DLK1-DIO3 locus305.  They report that IPW, a 
long noncoding RNA in the SNURF/SNRPN locus, is a regulator of the DLK1-DIO3 
region, as its overexpression in SNURF/SNRPN and parthenogenetic iPSCs resulted in 
downregulation of MEGs in this locus305.  The reported role of IPW is to facilitate the 
methylation of H3K9, thus reducing expression of the MEGs in the DLK1-DIO3 locus.  
The authors show that loss of imprinted genes in the SNURF/SNRPN locus leads to a 
trans effect where increased expression of imprinted genes in the DLK1-DIO3 locus is 
observed.  Our gene expression data seems to support this finding.  Taken together, this 
cross talk and the expression patterns we report might lay the foundation to finally 
elucidate a role for the imprinted snoRNAs. 
Given that snoRNAs are intronic74 and are processed under the action of the 
spliceosome we looked at snoRNA patterns in AML samples with mutations in splicing 
factors, SF3B1, SRSF2, and U2AF1.   Mutations in each of these genes has been shown 
to result in altered and distinct splicing patterns306.  One commonality was the reduced 
expression of a subset of snoRNAs.  It is noteworthy that intersecting the differentially 
expressed genes there were only 5 snoRNAs in common.  This reinforces the idea that 
these splicing factors elicit different alterations in splicing. U2AF1 recognizes the AG 
splice acceptor dinucleotide at the 3′ end of introns and mutations leads to exon skipping 
and/or retention.  Mutations in this gene seem to have a dramatic effect on snoRNA 
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expression as 93 of the differentially expressed snoRNAs are unique to it.  Several 
snoRNAs that modify critical PTC and ISB snoRNAs are differentially expressed 
suggesting that there might be some impact on ribosome biogenesis and thus translation. 
This is an area worthy of further investigation.  
As a whole, our study expands on the previous chapter and provides new 
expression data for snoRNAs in AML with an MLL translocation, core-binding factor AML, 
AML cases with a spliceosome gene mutation, and cases of APML.  We have ongoing 













Figure 3.1. Genomic organization of the fusion loci. A) Schematic representation of RUNX1, RUNXT1 and RUNX1-
RUNX1T1 genes. The red arrow indicates a breakpoint between exons e5 and e6 of the RUNX1 gene. The blue arrow 
indicates a typical breakpoint within the RUNX1T1 gene – between exons e1 and e2. The black arrow marks a junction 
between the RUNX1 (behind exon e5) and RUNX1T1 (in front of exon e2) genes. B) Schematic representation of MYH11, 
CBFB, and MYH11-CBFB genes. (i) The inversion fuses the 5′ end of the CBFB gene, located on 16q22, upstream of the 
3′ end of MYH11 on 16p13. (ii) The red arrow indicates a breakpoint between exons e5 and e6 of the CBFB gene. The blue 
arrow indicates a typical breakpoint within the MYH11 gene – between exons e11 and e12. The black arrow marks a junction 
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between the CBFB (behind exon e5) and MYH11 (in front of exon e12) genes. C) Schematic representation of the PML, 
RARA and PML-RARA genes. The red arrows indicate the three most common breakpoints in the PML gene:  between 
exons e3 and e4, within exon e6 and between exons e6 and e7. The blue arrow indicates a typical breakpoint in 
the RARA gene – between exons e2 and e3. The black arrows mark junctions: i. bcr1 – behind exon e6 of the PML gene 
and in front of exon e3 of the RARA gene; ii. bcr2 – within exon e6 of the PML gene and in front of exon e3 of 
the RARA gene; iii. bcr3 – behind exon e3 of the PML gene and in front of exon e3 of the RARA gene. D) Schematic 
representation of the structure of mixed-lineage leukemia (MLL) and normal versus aberrant MLL complexes. (i) The 
structure of the wild-type MLL protein, emphasizing the functional domains. MBD, Menin-binding domain; AT, AT hooks; 
SNL, speckled nuclear localization domains; RD, repression domains (black box in first RD represents the CXXC domain); 
BCR, breakpoint cluster region; PHD, PHD fingers; BD, bromodomain. CS1 and CS2 are the taspase-1 cleavage sites, and 
FYRN and FYRC are the domains whereby MLL-N and MLL-C interact after cleavage. TAD, transactivation domain; SET, 
H3K4 histone methyltransferase domain. (ii) MLL fusion proteins are caused by chromosomal rearrangements leading to 
in-frame fusions between N-terminal MLL (to the BCR) and any of 80 different possible fusion partners. PHD domains, 
transactivation domains, and the SET domain are typically lost. Images and legend reproduced/adapted from Atlas of 









Figure 3.2. Mutations that affect RNA splicing machinery are common in myelodysplastic syndromes (MDS) and 
AML. A) Mutations in genes that encode key components of the RNA splicing machinery are mutually exclusive and occur 
in a variety of cytogenetic contexts. Each column represents one patient sample with mutations shown as red bars. 
Karyotypic abnormalities represented here are: red, isolated deletion on the long arm of chromosome 5 [del(5q)]; green, 
−7/del(7q) alone or +1 abnormality; blue, isolated +8; yellow, isolated del(20q); black, complex; white, normal or −Y; orange, 
unknown. B) Schematic of RNA splicing showing spliceosome-mediated precursor-messenger RNA processing that causes 
the excision of an intervening intron housing a snoRNA to generate a snoRNA and ligation of flanking exons. C) Selected 
components of the spliceosome are typically mutated in MDS/AML. The U1 small nuclear ribonucleoprotein (snRNP) binds 
to the 5ʹ splice site (5ʹ SS), and the U2 snRNP binds to the branch point. The U2 auxiliary factor (U2AF), which is composed 
of U2AF1 and U2AF2 subunits, binds to the 3ʹ splice site (3ʹ SS) and polypyrimidine tract [Y(n)]. Serine- and arginine-rich 
proteins bind to the exonic splice enhancer (ESE). The genes encoding SF3A1, SF3B1, U2AF1, U2AF2, SF1, SRSF2, and 
ZRSR2 are mutated in myeloid neoplasms and are shown in red. (d) Schematic of U2AF1, SF3B1, and SRSF2’s mutational 
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landscape is shown. Outcomes of alternative splicing involving these splicing factors include alternative splice-site selection, 










Figure 3.3. Dendrogram showing unsupervised hierarchical clustering of snoRNA expression in 58 AML samples. 
Small RNA-seq was performed on 58 AML samples with the indicated genomic background and CD34 samples from 6 
healthy donors (Table 1). snoRNA expression (z-scored log2 RPM) is shown, with red indicating high expression, and green 
indicating low expression. Each column represents a unique snoRNA and each row represents a sample.   
 
 





Figure 3.4. Venn diagram of differentially expressed snoRNAs within each dataset. Venn diagram is used to show the 
intersection of the numbers of the differentially expressed snoRNAs in AML samples as characterized. The numbers in the 
intersections represent the absolute numbers of the comprised differentially expressed overlapping/unique snoRNAs, and 
the listing on the right represents the 36 differentially expressed snoRNAs common to all. 
 
 





Figure 3.5. SNURP-SNRPN locus snoRNAs have suppression expression in PML-RARa samples. A) Schematic 
representation of the SNURP-SNRPN domain in humans showing genes expressed from the maternal chromosome and 
snoRNAs expressed from the paternally inherited chromosome. Not drawn to scale. B) Expression of representative 
SNURP-SNRPN snoRNAs in CD34, PML-RARa and all other AMLs in study. 
 





Figure 3.6. DLK-DIO3 snoRNAs have increased expression in PML-RARa samples. A) Schematic representation of 
the DLK1-DIO3 domain in humans showing genes expressed from the paternal chromosome and snoRNAs expressed from 
the maternally inherited chromosome. Not drawn to scale. B) Expression of representative DLK-DIO3 snoRNAs in CD34, 
PML-RARa and all other AMLs in study. 
 






Figure 3.7. snoRNA differential expression plots for AML CBF (RUNX1-RUNX1T1 and MYH11-CBFB) fusions. Small 
RNA-seq was performed on 15 AML samples with RUNX1-RUNX1T1 (N = 4) and MYH11-CBFB (N = 11) fusions and CD34 
from 6 healthy donors (Table 1). Volcano plots show the significance level of the expression difference between A) all 
snoRNAs and B) all C/D box snoRNAs in samples with CBF fusions versus CD34. Each dot represents one snoRNA. The 
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horizontal line on the plot represents the P-level used for this analysis (0.05). Vertical lines represent the threshold for a 
twofold difference. The y-axis reflects the -log10(q value–corrected P value). Dots in the upper right and left quadrants 
represent differentially expressed snoRNAs which have absolute fold change value >2 and P ≤ 0.05. Differential expression 
and hierarchical clustering analyses were performed with the Partek Genomic Suite using log2 (read count per million 
mapped reads × 106 [RPM]) expression values for the curated sncRNA annotations as input; only RNA species (N = 303) 


























Figure 3.8. AML with splicing factor mutations have reduced expression of select snoRNAs. Volcano plot of the 
significance level of the expression difference between snoRNAs in samples with A) SF3B1, SRSF2, and U2AF1 and B) 
U2AF1 splicing mutations versus CD34. For A) small RNA-seq was performed on 16 AML samples with mutations in three 
splicing factors (SRSF2 - P95L (2), P95R (1); SF3B1 - E592K, Q19E (1), K700E (1); U2AF1 - Q157P (1), Q157P ASXL1 
(2), R156H (1), S34F (5), S34Y (1), and Q157R (1)) and CD34 from 6 healthy donors (Table 3.1 and Figure 3.1). For B 
analysis was between splicing factor mutation U2AF1 - Q157P (1), Q157P ASXL1 (2), R156H (1), S34F (5), S34Y (1), and 
Q157R (1)) and CD34. Each dot represents one snoRNA. The horizontal line on the plot represents the P-level used for 
this analysis (0.05). Vertical lines represent the threshold equivalent to a twofold difference. The y-axis reflects the q value–
corrected P value. Dots in the upper right and left quadrants represent differentially expressed snoRNAs which have 
absolute fold change value >2 and P ≤ 0.05.  Differential expression and hierarchical clustering analyses were performed 
with the Partek Genomic Suite using log2 (read count per million mapped reads × 10
6 [RPM]) expression values for the 
curated sncRNA annotations as input; only RNA species (N = 307) with mean normalized count values ≥5 were selected to 
produce reliable differential expression profiles.   
 






Figure 3.9. Unsupervised hierarchical clustering of snoRNA expression for AML with mutations in splicing factors. 
Small RNA-seq was performed on the indicated samples with mutations in splicing factors. snoRNA expression (z-scored 
log2 RPM) is shown, with red indicating high expression, and green indicating low expression. Each column represents a 
unique snoRNA, and each row represents a sample.  
 
 






Figure 3.10. Venn diagram of differentially expressed snoRNAs in AML samples with mutations in the indicated 
splicing factors versus healthy donors. Venn diagram shows the intersection of the numbers of the differentially 
expressed snoRNAs in AML samples characterized by mutations in splicing factors versus CD34 from six healthy donors. 
The numbers in the intersections represent the absolute numbers of the comprised differentially expressed 
overlapping/unique snoRNAs. 
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Table 3.3. Summary of the number of differentially expressed observed across all possible comparisons.  Samples 
included PML-RARa, CBF fusions, MLL fusions and AML with mutations in splicing factors. (P-value ≤ 0.05 and absolute 
fold-change ≥ 2.00) 
Names Number of  Elements 
CBF MLL PML SFM 36 SNORD18B SNORD114-22 SNORA72 SNORD118 SNORD83B SNORD38B SNORD19B SNORA28 SNORD1A 
SNORA1 SNORD113-8 SNORA40 SNORA63 SNORD105 snoID_0681 SNORD36C SNORD10 SNORA69 
SNORA46 SNORD114-12 SNORA20 SNORD113-6 SNORA26 SNORD114-9 SNORD114-21 SNORA51 
SCARNA7 SNORD29 snoID_0757 SNORD28 SNORD114-1 SNORD91B SNORD114-3 SCARNA14 SNORD5 
SNORA13 
CBF MLL PML 16 SNORA6 SNORD36A snoID_0378 SNORD114-14 SNORD113-5 SNORA34 SNORA10 SNORD113-9 snoID_0758 
SNORD114-26 SNORD113-7 SNORD114-23 SNORD114-17 SNORA62 SNORD114-28 SNORD114-25 
CBF PML SFM 13 SNORD11B SNORD72 SNORD4B SNORA96 SNORA4 SNORD34 SNORD77 SNORD14B SNORA33 SNORA79 
SNORD18C SNORD73A SNORD12B 
CBF MLL SFM 14 SCARNA8 SNORA58 SNORD56 SCARNA16 SNORD22 SNORA31 SNORD91A SCARNA4 SNORA9 SNORD104 
snoID_0409 SNORD138 14_70235681_70235822_+ SNORA75 
MLL PML SFM 2 SNORD86 SNORD116-20 
CBF PML 9 SNORD105B SNORD17 SNORA73B SNORA57 SNORA71A SNORD94 SCARNA20 SNORA71D SNORD76 
CBF MLL 4 SNORA58B SCARNA1 SCARNA9 SNORD90 
CBF SFM 8 SNORA36B SCARNA23 SNORD80 SNORD4A SCARNA9L SNORA97 SNORD70 SNORA32 
MLL PML 3 SNORD14C SNORA77 SNORD145 
PML SFM 5 SNORD116-27 SNORD116-12 SNORD116-14 SNORD116-16 SNORD116-15 
MLL SFM 4 SNORD12 SNORA66 SNORA80 SNORD88B 
CBF 9 SNORD97 SNORD117 SNORD47 SNORA76 SNORD84 snoID_0308 SNORD63 SNORD15A SNORD54 
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PML 38 SNORD88A snoID_0810 SNORD116-11 SNORD114-20 SNORA2A SNORA45 SNORD116-21 SNORD116-1 
SNORD116-8 SNORD116-29 SNORD114-11 SNORD64 SNORA74B SNORA5C SNORD116-25 SNORD112 
SNORD113.6-201 SNORD107 snoI_0409 SNORD113-4 SNORD116-24 SNORD89 SNORD25 SNORD116-2 
SNORD116-13 SCARNA10 SNORD116-22 SNORD116-6 SNORD113-3 SNORD116-26 SNORA11F SNORA7B 
SNORD116-23 SNORD114-15 SNORD49B SNORD114-10 SNORD114-13 snord138 
MLL 5 2_217366063_217366174_+ SNORD49A SNORD41 SNORA96(revised) SNORA53 
SFM 24 SNORD24 SNORA49 snoID_0386 SCARNA11 SNORD124 SNORD136 SNORA71B SNORA67 SNORD45C 
SNORD14E SNORD53 SNORD11 SNORD121A SNORD51 SNORD48 snoID_0699 SNORA65 SNORD65 



















Table 3.4. Summary of the number of differentially expressed observed across all possible comparisons. The 
splicing factor mutations are SRSF2, SF3B1, and U2AF1. Absolute fold change value >2 and P ≤ 0.05 




5 SNORA58 SNORD113-6 SNORD104 SNORA51 SNORD70 
SF3B1 
SRSF2 
17 SNORD114-22 SNORD114-14 SNORD113-5 SNORD113-9 SNORD113-8 SNORD114-26 SNORD114-12 SNORD46 SNORD113-7 






21 SNORD24 SNORA72 SNORD136 SNORD83B SNORD118 SNORD4B SNORD1A SNORA40 SNORA96 SNORD53 snoID_0681 SNORA46 
SNORD48 SNORD116-16 snoID_0409 SCARNA9L SNORD29 SNORD116-15 14_70235681_70235822_+ SCARNA14 SNORA13 
SF3B1 6 SNORA74A SNORD16 SNORA73B SNORD63B SCARNA28 SNORD15A 
SRSF2 25 SNORA42 SNORD116-11 SNORD116-21 snoID_0378 SNORD1C SNORD116-1 SNORD64 SNORD116-25 SNORD92 SNORD116-27 
SNORD116-12 SNORD116-24 SNORD89 SNORD116-13 SCARNA2 SNORD114-17 SCARNA7 SNORD116-14 SNORD19C SNORD116-22 
SNORD50A SNORD116-23 U8.4-201 SNORD102 SNORD116-20 
U2AF1 93 SNORD14A SNORA58B SCARNA8 SNORD67 SNORA49 snoID_0386 SNORA8 SNORD11B SCARNA11 SNORD32A SNORD72 SNORD18B 
SNORA12 SNORD124 SNORA36B SNORA66 snoID_0728 SNORD45A SNORD56 SNORD38B SNORD19B SNORA71B SNORD14C 
SNORA28 SCARNA1 SNORA1 SNORA67 SCARNA23 SNORD45C SNORA74D SNORA44 SCARNA16 SNORD14E SNORD22 SNORA63 
SNORD105 SNORA31 SNORD91A SNORD36C SNORD10 SCARNA4 SNORA4 SNORD11 SNORA50 SNORD34 SNORD146 SNORA69 
SNORA9 SNORD121A SNORD51 SNORA20 SNORD36B SNORD80 SNORD25 SNORA18 SNORD77 SNORD14B SNORA53 SNORD86 
SNORA33 SNORA26 SNORD43 SNORD4A SNORA24 SNORA65 SNORD65 SNORD70B SNORA79 SNORD98 SNORD54 SNORD18C 
SNORD8 SNORD12C snoID_0757 SNORA68 SNORA25 SNORD28 SNORA73A SNORA101B SNORD138 SNORA75 SNORA97 SNORD91B 
SNORA17 SNORD5 SNORD73A snoID_0680 SNORD100 SNORA14B SNORA77B SNORA21 SNORD12B SNORA32 
 































Mature blood cells are produced through a series of stepwise hierarchical 
progression of differentiation where hematopoietic stem cells and increasingly committed 
progenitors progress unidirectionally to mature circulating blood cells307-309.  Considerable 
understanding has been acquired into lineage commitment at the transcriptional 
level310,311, yet there remains much uncertainty about the molecular control of self-
renewal, lineage determination and clonal integrity. The rate of protein synthesis varies 
considerably during hematopoietic differentiation312-314.  Signer et al., reported that 
precise regulation of protein synthesis rates is required for hematopoietic stem cell (HSC) 
function312.  Moreover, increased protein synthesis has been implicated in the 
development of certain cancers, including hematopoietic malignancies315-317.   Recent 
human genetics, biochemical and proteomic studies have shown that ribosomes play a 
critical role in promoting lineage commitment from HSPCs318,319.  Indeed, mutations that 
affect ribosome function are associated with impaired hematopoiesis177,178.   Taken 
together, these observations highlight the importance of translational control in the 
regulation of normal and malignant hematopoiesis. 
There is an emerging consensus that regulation at the level of the ribosome 
through modification of rRNAs play an important role in ribosome biogenesis, translational 
control, and the generations of specialized ribosomes320.  rRNAs are highly modified, 
containing over 110 modifications, the most common of which are base pseudouridylation 
and ribose 2’-O-methylation mediated by snoRNAs320.  On a molecular level, 
pseudouridylation leads to increased rotational freedom about the glycosyl bond and the 
creation of an extra hydrogen bond donor118,321,322.  These changes have the effect of 
increasing base stacking and stabilizing double stranded base pairing interactions critical 
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for inter- and intramolecular binding properties in evolutionarily conserved regions118,322.  
One such region where these modifications are concentrated is the peptidyl transferase 
center (PTC) which is the ribosomal catalytic site where peptide bonds are made during 
protein elongation and peptidyl-tRNAs are hydrolyzed during the termination of protein 
synthesis286.  Studies in yeast, suggest that loss of pseudouridylation or 2’-O methylation 
at individual and clusters of PTC sites results in reading frame changes, altered transfer 
RNA (tRNA) selection, increased stop codon read through, amino acid incorporation 
defects, altered polysome patterns, and reduced translational efficiency118,128,288.   
The importance of pseudouridylation in human hematopoiesis is illustrated by 
dyskeratosis congenita, a congenital bone marrow failure syndrome.   The X-linked form 
of dyskeratosis congenita is due to loss of function mutations of DKC1 which is a 
pseudouridine synthase that along with H/ACA snoRNAs carries out pseudouridylation.  
Loss of DKC1 in murine cells is associated with reduced levels of pseudouridine in rRNA, 
impaired ribosome biogenesis, and reduced translation of genes with an 
internal ribosome entry site (IRES) motif in their 5’-untranslated region125,228,323,324.  
Patients with DKC1 mutations also have impaired telomere maintenance, which likely 
contributes to the impaired hematopoiesis.   Although there is strong evidence in mice 
that DKC1 regulates hematopoiesis in a non-telomere dependent fashion, this is not 
proven in humans.  Interestingly cancer incidence in patients with DC is 11 times higher 
than in the general population320. 
snoRNAs are one of the largest classes of noncoding RNAs in eukaryotes. They 
guide the site-specific 2′-O-ribose methylation (C/D box snoRNAs) and pseudouridylation 
of rRNAs (H/ACA box snoRNAs) via base complementarity and assist in the cleavage of 
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pre-rRNAs thus playing an essential role in ribosome biogenesis3,240,298,325.   Originally 
thought of as simply playing a housekeeping role, they have now been implicated in 
alternative splicing,254 regulation of chromatin structure,255 metabolism,168 and neoplastic 
transformation204,326.   Specifically, numerous reports have recently implicated 
snoRNAs99,102,192,327 in acute myeloid leukemia.   For example, a recent paper looking at 
AML-ETO fusion AMLs reported that C/D box snoRNAs and rRNA 2'-O-methylation play 
a critical role in leukemic stem cell activity102.  
Our group recently profiled the snoRNA expression in de novo AML with normal 
karyotype192.   We reported that a subset of snoRNAs is expressed in a developmental- 
and lineage-specific manner during human hematopoiesis192.  Expression of most 
snoRNAs in AML was comparable to that observed in CD34 cells from healthy, consistent 
with a housekeeping function for snoRNAs.   However, SNORA21 expression was 
modestly, but significantly reduced in normal karyotype AML, and its expression varied 
more than 10-fold between AML samples.    SNORA21 modifies two positions with the 
PTC of the 28S rRNA (U4401 and U4470)328,329.    Deletion of snR10, the orthologue of 
SNORA21 in yeast26,330 results in the complete loss of pseudouridylation at the 
orthologous ribosome position, as well as altered ribosome structure, biogenesis and 
activity118.   The contribution of SNORA21 in the regulation of ribosome function in human 
cells is largely unknown.   However, increased SNORA21 expression is associated with 
poor prognosis in patients with gastric, colorectal, or lung cancer.   
Here we show that reduced SNORA21 expression is reduced, but highly variable, 
in multiple genetic subtypes of AML.  Loss of SNORA21 in K562 cells is associated with 
impaired ribosome biogenesis and reduced global translation.   It also induces a non-
 
           105
 
 
apoptotic cell death characterized by impaired mitochondrial function.  These 
observations suggest that alterations in SNORA21 expression in human AML may 


























Primary cell culture  
K562 human chronic myelogenous leukemia (CML) cells were obtained from ATCC and 
grown in Iscove’s Modified Dulbecco’s Medium (ThermoFisher) supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (Atlas Biologicals, Larimer Colorado) and 1% 
(v/v) penicillin-streptomycin (Life Technologies, Inc.).   Cells were maintained at a density 
of 1.0 - 1.5 x 106 cells/mL at a viability of 94 - 97% in a humidified atmosphere at 37 °C 
in 5% CO2. 
 
Generation of Cas9-expressing clonally derived cells 
K562 cells stably expressing a constitutive rtTa were transduced with a lentivirus that 
expresses spCas9 under tetracycline-controlled promoter, where Cas9 expression is also 
linked to mCherry via an internal ribosome entry site (IRES).  Once K562 cells were 
transduced, Cas9 expression was induced by doxycycline (500ng/mL) for 48h and 
clonally derived cells were established by sorting GFP+ cells into a well of a 96-well place 
using fluorescence-activated cell sorting (FACS) buffer.  These cells were subsequently 
used to delete SNORA21. 
 
Deletion of SNORD21 in K562 cells 
Using the web interface of UCSC Genome Browser’s CRISPR design software 
(https://genome.ucsc.edu/), multiple small guide RNAs (gRNAs) targeting spanning 
SNARDA21 gene.  Offtarget activity of these gRNAs were further evaluated with Blastn 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi).  Briefly, two complementary oligos were 
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designed to generate double stranded gRNA with flanking BsmBI restriction sites.  For 
example, one of the sequences of human sgRNAs targeting the 5’ end of SNORD21 (5’ 
-> 3’) is ATTTTGAAGAAGGGCCGTCG.  Briefly, two complementary oligos were 
designed to generate double stranded gRNA with BsmBI restriction sites (5’ -> 3’): 
CACCG-ATTTTGAAGAAGGGCCGTCG and AAAC-CGACGGCCCTTCTTCAAAAT-C. 
These oligos were self-annealed and cloned into BsmBI digested LRB plasmid 
(Lenti_sgRNA_EFS_GFP; Addgene #65656).  Clonally derived K562 cells with inducible 
Cas9 were treated with doxycycline (500ng/mL) for 48h, co-nucleofected LRG vector 
expressing aforementioned sgRNAs. 48-hours post-transduction, stable cell lines 
expressing both Cas9-GFP and sgRNA-BFP were established by sorting GFP+ BFP+ 
cells by FACS. Upon expansion of these cells, a PCR-based approach was performed to 
validate successful deletion of the target region.   
 
Experimental validation of CRISPR/Cas9  
Genomic DNA was extracted from the SNORA21−/− and wild type K562 using the 
PureLink Genomic DNA Kit, (Invitrogen) according to the manufacturer’s instruction.  A 
pair of primers (Primers F1: 5’..TGAGCTCTGGTTTGCCTTTCTTG..3’                            
R1: 5’..GTGAATTACAGCTTGAGTATGAG..3’) that amplify a region spanning the gene 
deletion area (584nt region, wild type cells; 435nt, SNORA21−/− K562 cells) were 
designed using NCBI primer design tool (https://www.ncbi.nlm.nih.gov/tools/primer-
blast/).   For PCR, 5 µl of GoTaq green master-mix (Promega, Madison, WI) and 0.2 µL 
of each of the forward and reverse primers (20 µM final conc; Integrated DNA 
Technologies) were added per PCR tube (0.2 mL; ThermoFisher). Finally, 2 µl of 
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genomic DNA sample and 3 µl of nuclease-free water were added to each tube for a 
final reaction volume of 10 µl. PCR was performed using a standard thermocycler (Bio-
Rad T100 Thermal Cycler).  The PCR conditions were as follows: Initial denaturation 
(95 °C for 2 minutes), followed by 35 cycles of denaturation (95°C for 30 secs), 
annealing (56 °C for 30 secs) and extension (72°C for 45 secs) and a final extension at 
72°C for 5 minutes.  PCR products were removed from the thermocycler and 
maintained at room temperature for a few minutes before loading on the 2% agarose 
gel.  7 µl of each PCR sample was loaded into each well and electrophoresis was 
performed for 1 hour and 20 minutes at 100 volts. The power supply (Thermo Scientific 
EC Electrophoresis Dual Power Supply EC135-90) was set to 100 V. A DNA size 
marker (100 bp DNA even ladder, EZ BioResearch, St. Louis, MO) was used.  Gel 
images were acquired using a regular gel-documentation system (ChemiDoc MP 
Imaging System, Bio-Rad, Hercules, CA). Separately, SNORA21 deletion was detected 
by PCR-based 2× bidirectional direct Sanger sequencing using the primers specified 
above.  The sequencing results were interpreted using SerialCloner v6-3-1 software.  
 
Cell proliferation assays  
Cells were plated in triplicate in 6-well plates (100,000 cells/well) with growth medium. 
Cells were counted in triplicate at the indicated time points with a Bürker chamber cell 
chamber after 0.2% Trypan Blue staining to exclude apoptotic/necrotic cells. Separately, 
the cells were counted on a Cellometer (Nexcelom Bioscience, Lawrence, MA) and plated 
at 1 000 cells per well in 150 μL of media on a 96-well plate in triplicate.  Each well was 
treated with 1 μM of IncuCyte® NucLight Rapid Red Reagent (Essen Biosciences, Ann 
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Arbor, MI).   With an Incucyte live cell imager (Essen Biosciences), photomicrographs 
were recorded every 12 hours for a total of 156 hours. At each time point, each culture 
was scanned 5 times at a 10x objective.   For each culture at each time point, the Incucyte 
software was used to measure the mean number of red-positive cells from the 5 non-
overlapping images, and these counts were taken as the number of live cells in each 
culture.  The counts for the cultures at the 0-hour time point were averaged to yield a 
baseline count for the starting point.  All counts were normalized to the baseline and 
presented as a fold change from the baseline. 
 
Caspase-3/7 activity assay 
The caspase-3/7 activity in the cell extracts was determined using Caspase-Glo 3/7 
Assay (Promega) according to the manufacturer’s instructions98.   In brief, K562 cells 
were seeded in the inner wells of a white, 96-well plate (Corning Costar, Corning, NY) at 
10,000 cells per well (100µl) in replicates of three and incubated at 37°C with 5% CO2. 
An equal volume of the Caspase-Glo® 3/7 Reagent was added directly to the cells in 96-
well plates with brief agitation and incubated at 25°C for 1 hour.   Caspase-Glo® 3/7 
luminescent signal was read on the Xenogen IVIS 50 Imaging System (Caliper Life 
Sciences, Waltham, MA).  Background fluorescence signals (media-only wells) was 
subtracted from all values, and averages and standard deviations were calculated from 
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Flow cytometric analysis of apoptosis.  
Cells were washed once in PBS and resuspended in Annexin binding buffer 
(Biolegend) and stained with FITC-conjugated Annexin V and PI (Biolegend) per the 
manufacturer’s instructions.  After staining, cells were washed with Annexin binding 
buffer, resuspended in a fixing solution and stored at 4°C in the dark.  Flow cytometry 
was performed on a FACScan (Beckman Coulter). All flow cytometry files were analyzed 
with FlowJo software (Tree Star, OR). 
 
Cell cycle analysis  
Cells were counted by trypan blue exclusion and resuspended to a concentration of 1 × 
106 cells/ml in FACS buffer.  They were then washed in ice-cold PBS followed by fixation 
and permeabilization using the Cytofix/Cytoperm Fixation Permeabilization Kit (BD 
Biosciences) followed by incubation at room temperature for 10 min in 1 x BD Perm/Wash 
buffer supplemented with 5% goat serum. Alexa Fluor® 700 anti-human Ki-67 Antibody 
(BioLegend) was then added and allowed to incubate on ice for 30 min followed by 
washing with 1x BD Perm/Wash buffer and resuspension in FACS buffer.  Cells were 
stained for DNA content by FxCycleTM Violet DNA dye (Invitrogen) according to the 
manufacturer’s protocol.   Flow cytometry was performed on a FACScan. All flow 
cytometry files were analyzed with FlowJo software. 
 
Proliferation measurement via EdU incorporation 
A Click-iT EdU (5-ethynyl-2′-deoxyuridine) cytometry assay kit (Invitrogen) was used for 
the labeling and detection of newly synthesized DNA.  The labeling depended on the 
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incorporation of the thymidine analog EdU followed by a copper catalyzed cycloaddition 
reaction analog with an azide-conjugated fluorophore for flow cytometry detection.  The 
assay followed the manufacturer’s protocol with some modification based on optimization 
for K562 cells.  In brief, 1×106 WT and SNORA21-/- K562 cells were fixed and 
permeabilized 2 hours post-EdU administration.  A copper catalyzed cycloaddition 
reaction between an alkyne of EDU and a dye labeled azide occurred followed by flow 
cytometric analysis.  The background staining of K562 cells not incubated with EdU was 
used as a negative control331,332. 
 
Measurement of global protein synthesis 
Ribosome activity was determined using puromycin labeling of nascent peptides that 
were detected at the single cell level312,333.  After optimization, metabolic labeling assays 
were performed using 1x106 K562 cells per assay.  Cells were collected by centrifugation 
and washed in ice-cold phosphate-buffered saline (PBS).  They were incubated in OPP, 
20 mM (Click-iT™ Plus OPP Alexa Fluor™ 488 Protein Synthesis Assay Kit, Life 
Technologies) for 30 minutes.  They were then washed in ice-cold Ca2+- and Mg2+-free 
PBS followed by fixation in cell fixation and permeabilization solution (BD Biosciences) 
for 20 minutes followed by a BD Perm/Wash™ Buffer (1x) wash (BD Biosciences).  The 
azide–alkyne click chemistry cycloaddition was performed using the Click-iT Cell 
Reaction Buffer Kit (Thermo Scientific) as described in the manufacturer’s instructions 
with the azide conjugated to Alexa Fluor 488.  After 30 min, samples were washed with 
Click-iT® Reaction Rinse Buffer then with PBS/3% BSA and resuspended in 
fluorescence-activated cell sorting buffer before data acquisition using a FACS flow 
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cytometer (BD Biosciences).  Data analysis was performed using FlowJo v10.1.  To 
determine if protein synthesis is required for OPP incorporation into nascent polypeptides, 
cells were incubated for 30 mins at 37°C in a humidified 5% CO2 atmosphere with culture 
medium supplemented with 100ug/ml cycloheximide (CHX).  This concentration of CHX 
was determined a priori to essentially block protein translation in K562 cells.  All assays 
were performed in triplicate.  Data was expressed as mean signal intensity. A one-way 
analysis of variance (ANOVA, p<0.001) was applied to the data. 
 
Ribosome Profiling  
Equal amounts of total RNA from the supernatant was layered over a 10%–50% sucrose 
gradient (20 mM Tris-HCl pH 7.5; 140 mM KCl (Invitrogen/Thermo Fisher); 5 mM MgCl2; 
0.5 mM DTT) and centrifuged at 37,000 rpm for 160 min at 4ºC in a SW41Ti rotor 
(Beckman Coulter).   Gradients were displaced from the bottom up with a BR-188 Density 
Gradient Fractionation System (Brandel, Gaithersburg, MD) by a chase solution (60% 
sucrose (IBI Scientific, Dubuque, IA) with bromophenol blue (Sigma, St. Louis, MO)) at a 
rate of 1.50 ml.min−1 combined with continuous absorbance reading at A254 nm.   Traces 
were recorded at a sensitivity setting of 2.  Area under the curve was calculated using 
GraphPad Prism.  Statistical significance was calculated with Student’s t-test. P-values < 
0.05 were considered significant.   
 
RiboSeq 
The ribosome profiling strategy was adapted from Mc.Glincy and Ingolia334 and based on 
De Klerk et al.,335 with some modifications.  Supernatant from the cleared lysate 
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corresponding to 250ug of total RNA were incubated with 300 Units of RNase T1 (Thermo 
Scientific, Waltham, MA) and 500ng of RNase A (Invitrogen/Thermo Fisher) for 15 
minutes at room temperature with gentle shaking at 350 rpm.   Digestion was blocked 
with SuperaseIN (Ambion/Thermo Fisher) and the lysate was layered on 600ul of a 1M 
sucrose cushion.   The sample was ultracentrifuged in an Optima Max-XP ultracentrifuge 
(Beckman Coulter) equipped with a MLA-130 rotor at 4ºC for 4 hours at 70,000 rpm.  The 
pellet was resuspended in 700μl of TRizol reagent (Invitrogen/Thermo Fisher) and RNA 
extracted using the Direct-zol RNA MiniPrep (Zymo) per the manufacturer’s instructions. 
Cytoplasmic and mitochondrial rRNAs were removed using NEBNext® rRNA Depletion 
Kit (NEBL) according to manufacturer's instructions, with modifications.  RNA Clean and 
Concentrator-5 (Zymo) was used for cleanup post ribo depletion.   Purified RNA was 3’ 
end dephosphorylated using 10U of T4 PNK (NEBL) at 37ºC for 3 hours followed by 
cleanup with RNA Clean and Concentrator-5 (Zymo).  The yield and quality were 
assessed using the Qubit microRNA assay (ThermoFisher) and the Agilent 2200 
TapeStation system (Agilent Genomics). 
Library preparation were carried out as previously described by Warner et al., 
2018.  Libraries were sequenced on an Illumina NextSeq 500 high output flowcell as a 
2x40 by the DNA Sequencing Innovation Lab at the Center for Genome Sciences and 
Systems Biology, Washington University St. Louis, MO. Raw FASTQ files 
were demultiplexed using the Illumina bcl2fastq2 script.  Illumina adapters were filtered 
using fqtrim.  Reads were aligned to the human genome (hg19) using TopHat2, version 
2.0.11 using a guided alignment strategy using Ensembl gene annotations (GRCh37 
v82)336.  TopHat2 has previously been shown to be an effective aligner for short RNA 
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sequencing libraries334.  Mapped reads were assigned to Ensembl gene annotations and 
duplicate reads removed using featureCounts.  
 
Transcriptome sequencing 
Trizol extracted RNA was purified on RNA Clean & Concentrator-5 (Zymo) using the 
manufacturer's protocol.  The Qubit RNA HS Assay Kit (Life Technologies) and the Agilent 
2200 TapeStation system were used for quantification and quality assessment, 
respectively, according to the manufacturer's instructions.  Library preparation was 
carried out using the KAPA Biosystems RNA Hyper Prep with Riboerase (KAPA Chicago, 
IL) according to manufacturer’s recommendation.  Cycle numbers were optimized using 
qPCR. NGS sequencing performed on an Illumina NextSeq 500 as a 2x150 configuration 
by the DNA Sequencing Innovation Lab at the Center for Genome Sciences and Systems 
Biology.  Illumina adapters were filtered using fqtrim.  Processed reads were aligned to 
the human genome (hg19) using HiSat2, Version 2.1.0337.  Mapped reads were assigned 
to Ensembl gene annotations (GRCh37 v82) and duplicate reads removed using 
featureCounts.  Separately, data analyses (cluster, principle component analyses, 
biofunctional analysis, differential expression) was carried out using the Partek Flow. 
Reads were mapped to the National Center for Biotechnology Information Build 37 human 
reference sequence by STAR (v. 2.5.3a) and normalized FPKM values were determined 
using Partek Genomic Suite.  The Partek gene specific analysis (GSA) algorithm was 
utilized for differential expression analyses.   Differentially expressed genes were selected 
at ≥2-fold difference (comparing wildtype and snorna21-/- K562 samples) and P< 5.00E-
2.  Results were validated with RT-PCR. We searched for genes with significantly 
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increased or decreased translational efficiency338 (TE) (mRNA abundance vs ribosome 
occupancy) using RiboDiff339.  We selected genes significant at an adjusted P< 5.00E-2 
and showing log2(TE SNORA21−/−/TEWT) higher or lower than 0.00. 
 
Analysis of pseudouridylation 
The 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimide metho-p-toluenesulfonate (CMCT) 
treated samples were essentially prepared as previously described51,119,120,328,340-345 with 
some exceptions.  Incubation time, temperature, pH and the ratio of amounts of CMCT to 
sample were optimized.  Ten µg of RNA was resuspended in a solution of freshly 
dissolved made CMCT in Bicine buffer (50 mM bicine pH 8.3, (Hampton Research, Aliso 
Viejo, CA), 4 mM EDTA (Invitrogen), and 7 M urea (Sigma) for a final concentration of 
0.2 M CMCT.  The mixture was incubated at 37°C for 20 minutes.  The CMCT-RNA was 
ethanol purified and resuspended in 40 µL of 50 mM sodium bicarbonate (Sigma) and 
incubated at 37°C for 4 hours.   Following ethanol purification, reverse transcription with 
SuperScript III RT (Thermo Scientific, ) was conducted on 1 µg RNA in 8mM MgCl2, 50mM 
Tris pH 8.3, 75 mM KCl, 10mM DTT, 0.5mM dNTPs  and primers (RT primer 28S), IDT), 
at 42ºC for 3 hrs in a total volume of 10 µL.   The samples were incubated at 90°C for 
5 minutes to end the reverse transcription reaction.  The cDNA was amplified in a 10 µL 
reaction (EconoTaq Plus Green 2X Master Mixes, Lucigen, Middleton, WI), primers, 
template) for 20 cycles.  The indexes were added in a 20 µL reaction (EconoTaq Plus 
Green 2X Master Mixes, primers, template) with 8 cycles.  The DNA was separated on a 
gel containing 2.0% agarose (MidSci) gel with 6X loading dye (NEBL).  After gel 
electrophoresis, primer extension was visualized by ultraviolet light. The region of interest 
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of each lane was excised, and the DNA extracted using Zymoclean Gel DNA Recovery 
Kit (Zymo).  The library was checked by Agilent 2200 TapeStation system and then 
sequenced in a MiSeq (Illumina) at the DNA Sequencing Innovation Lab at the Center for 




For an autophagy positive control, cells were amino acid starved by extensively washing 
with Hank's Balanced Salt Solution (HBSS) (Gibco) and further incubated in HBSS for 3 
and 6 hrs as described elsewhere346,347.  Cell suspensions were fixed in 2.5% 
glutaraldehyde (Electron Microscopy Sciences (EMS), Hatfield, PA), 2% 
paraformaldehyde (EMS) in 0.15 M cacodylate buffer: sodium cacodylate (EMS) with 
4 nM CaCl2 (EMS).  Following several buffer rinses, cells were mixed with low 
temperature gelling agarose (MP Biomedicals, LLC, Solon, OH) and pelleted.  The 
cell/agarose pellets were trimmed into 1-2 mm blocks for the remaining preparation steps. 
Cell blocks were then post fixed in a 1% OsO4 (EMS)/1.5% FeKCN mixture (EMS) for 1 
hr. in the dark, en block stained in 2% uranyl acetate (EMS) for 2 hrs and subsequently 
dehydrated in 100% ethanol (EMS) (3X 10min each), infiltrated in 50%, and 100% (3x) 
LX112 Resin (EMS) (microwave assisted), and cured at 60◦C for 48 hrs.  Sections were 
cut using a diamond knife on a Leica EM UCT7 ultramicrotome (Leica Microsystems 
GmbH, Wetzlar, Germany) then post stained in 2% uranyl acetate followed by Reynolds 
lead citrate (lead nitrate (EMS) and sodium citrate (EMS)348 and viewed on a JEOL 1400 
Plus transmission electron microscope (JEOL USA, Inc. Peabody, MA) operated at 
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120 kV.  We collected more than one hundred images for both cell types obtained three 
independent experiments. 
 
Ferroptosis induction and inhibition 
K562 cell lines were exposed to varied concentrations (10, 5, 1 μM) of the ferroptosis 
inducer, erastin-glutathione depletion (Sigma) either alone or in combination with the lipid 
peroxidation inhibitor, ferrostatin-1 (Sigma, 10 μM). DMSO (0.1%) was used for vehicle. 
Cell viability was assessed by Incucyte.  
 
Analysis of mitochondria mass and reactive oxygen species production 
Cells were incubated with Mito-Tracker Green (MTG), (25nM, Invitrogen) at 37°C for 30 
min, washed in 1X PBS/2% BSA as previously described349.  MTG selectively 
accumulates in the mitochondrial matrix where it covalently binds to mitochondrial 
proteins by reacting with free thiol groups of cysteine residues349.  For the lipophilic 
fluorophore C11-BODIPY581/591 which localizes in subcellular membranes and “senses” 
lipid peroxidative damage in these compartments350,351 the cells were incubated with 5 
uM  BODIPY for 30 min at 37 °C, as described351.  For a positive control, cumene peroxide 
(100 uM) was added followed by incubation for 2 hrs at 37C.  SYTOX blue was added 
and incubated for 15 min followed by flow cytometric cell sorting on an Attune flow 
cytometer (ThermoFisher). Data were analyzed using FlowJo 9.9.3 (TreeStar).  
 
 




The sequencing data will be deposited to National Center for Biotechnology Information 
Gene Expression Omnibus database.  
 
Statistical analysis  
For statistical comparison of two groups, unpaired two-tailed Student’s t test was used. 
When more than two groups were compared, one-way ANOVA followed by multiple 
comparisons test was performed using Prism version 7.00 for Mac (GraphPad). 
Differences among group means were considered significant when the probability value, 
p, was less than 0.05.  Sample size (n) represents biological replicates. No statistical 


















Differential expression of snoRNAs targeting the PTC domain of rRNA.   
We previously reported that SNORA21 expression is reduced approximately 2-fold in de 
novo AML compared to CD34 cells from healthy donors.   To extend this observation, we 
sequenced the small RNA transcriptome of an additional 65 cases of AML, including AML 
carrying chromosomal translocations and deletion and/or mutations in spliceosome 
genes as reported in chapter 3.   Compared to normal CD34 cells, SNORA21 expression 
was significantly reduced in AML carrying mutations in spliceosome genes, core binding 
factor genes, and MLL translocations (Figure 4.1A).   In addition, marked variability in 
SNORA21 expression was observed with a given AML genetic subtype.   For example, 
in spliceosome mutated AML, SNORA21 expression varied more than 100-fold.  Given 
the critical role that PTC snoRNAs play in translation fidelity, we next looked at the 
expression of other snoRNAs that target the PTC domain of the ribosome (circled in 
Figure 4.1B).   Although considerably variability was observed, expression of most of 
these PTC-snoRNAs in AML was similar to that seen in normal CD34+ cells (Figure 4.1C-
D). 
 
Generation of SNORA21-/- K562 cells   
To examine the contribution of SNORA21 to ribosome biogenesis and function, we used 
CRISPR-gene editing to delete SNORA21 from K562 cells, an erythroleukemia cell line.  
SNORA21 is located in the intron of the host gene RPL23.   We designed the guide RNA 
to target a region included in the mature SNORA21 (Figure 4.2A).   The SNORA21 gRNA 
complexed to recombinant Cas9 was transfected into K562 cells and three independent 
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clones were obtained by limiting dilution cloning.   Sanger sequencing confirmed 
disruption of the SNORA21 gene (Figure 4.2B), and RNA sequencing confirmed the loss 
of SNORA21 expression; however, expression of RPL23 was not affected (Figure 4.2C-
D).  We measured rRNA pseudouridylation at rRNA28S-4470 and rRNA28S-4401, sites 
which are targeted by SNORA21.   We predict that our ongoing data analysis will reveal 
a loss of pseudouridylation at these sites. 
   
Loss of SNORA21 results in decreased ribosome function 
In yeast, loss of pseudouridylation at U2919 in the 25S rRNA subunit is associated with 
impaired ribosome biogenesis, function, and altered translation118.   To quantify ribosome 
biogenesis and assembly into polysomes, we performed polysome profiling on 
SNORA21-/- K562 cells.   Steady-state levels of the small 40S and large 60S ribosomal 
subunits was comparable to control cells (Figure 4.3A-B).   However, there was a 
significant decrease in 80S (monosomes) and a trend to a decrease in polysomes (Figure 
4.3A-B).   To assess global protein synthesis, we next employed an assay that uses O-
propargylpuromycin (OP-Puro), an alkyne analog of puromycin, and click chemistry to 
label nascent polypeptide chains333.  The amount of OP-Puro incorporation in  
SNORA21-/-  K562 cells was reduced by approximately 40% compared to control cells. 
(Figure 4.3C-D).   Collectively, these data show that loss of SNORA21 results in impaired 
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SNORA21 deletion in K562 cells has a modest impact on translational efficiency 
There is evidence that altered ribosome function can result in selective changes in the 
translation of mRNAs154,352,353.   Recent studies indicate that in DKC1-depleted cells with 
resultant reduction in pseudouridylation, the impact of the alteration in IRES-mediated 
protein synthesis is bifurcated: 1) reduced translation of anti-apoptotic factors (Bcl-xL and 
XIAP) and tumor suppressors (p27 and p53)152,354  or 2) increased translation of other 
IRES-containing transcripts such as VEGF and heat shock protein 70 mRNAs149.  Thus, 
we next performed active mRNA translation sequencing (RiboSeq), which quantifies 
mRNA that are being translated.   In brief, ribosomes complexed to mRNA are digested 
with ribonucleases to degrade RNA not protected by ribosomes.   The protected RNA is 
subjected to next generation sequencing.   In parallel, standard RNA sequencing is 
performed to allow for a calculation of translational efficiency, using RiboDiff339.  The 
majority of genes showed no difference in translational efficiency (Figure 4.4A).   Indeed, 
only 145 genes showed a difference in translational efficiency, as defined by an adjusted 
p-value of < 0.01 and a > 2-fold change (Supplementary Table 4.1).   Interestingly, the 
great majority (90%) of these genes showed increased translational efficiency (Figure 
4.4B).   Of note, no enrichment for TOP mRNAs characterized by an oligopyrimidine tract 
at the 5’ terminus was observed.   These data show that loss of SNORA21, despite the 
overall decrease in translation, has a modest impact on the translational efficiency of 
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SNORA21 deletion in K562 cells induces a non-apoptotic cell death 
We next assessed the impact of the loss of SNORA21 on cell growth and survival.   Cell 
proliferation was measured using manual cell counts and validated using the IncuCyte® 
live-cell analysis system.   In each case, cellular proliferation of SNORA21-/- clones was 
markedly reduced (Figure 4.5A-B).   Cellular proliferation is a function of the rate of cell 
division and cell death.   Cell cycle status was measured using the FxCycleTM Violet DNA 
dye.  Surprisingly, compared with control cells no difference in the percentage of cells in 
the S or G2/M phases of the cell cycle were observed (Figure 4.5C-D).   Likewise, the 
rate of DNA synthesis, as measured by EdU incorporation was similar between control 
and SNORA21-/- cells (Figure 4.5E-F).   We next asked whether loss of SNORA21 
induced apoptosis.   However, no increase in activated Caspase 3/7 or cell surface 
annexin-V expression was observed in SNORA21-/- cells (Figure 4.5G-H).   The decrease 
in cell proliferation despite the normal rate of cell division and absence of apoptosis 
suggest that loss of SNORA21 is inducing a non-apoptotic cell death.   
 
SNORA21-/- K562 cells have altered mitochondrial morphology  
Prior studies suggested that impaired ribosome function can induce autophagy355-357.  
Indeed, gene set enrichment and pathway analysis of transcriptome sequence data from 
SNORA21-/- K562 cells identified a molecular signature for phagosomes and translation 
(Figure 4.6 A-B).   Thus, to determine whether loss of SNORA21 induced autophagic cell 
death, we performed transmission electron microscopy on SNORA21-/- K562 cells.   As a 
positive control, we also analyzed wildtype K562 cells that were serum starved for 3 and 
6 hours to induce autophagy.   A consistent finding in autophagy is the presence of large, 
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double-membrane enclosed vesicles358.  Indeed, autophagosomes were readily 
observed in serum starved wildtype K562 cells (Figure 4.7A-B).   However, they were 
not observed in SNORA21-/- K562 cells (Figure 4.7C). Instead, SNORA21-/- K562 cells 
displayed two consistent features.   First, many of the cells demonstrated a loss of 
membrane integrity, which is indicative of cell necrosis (Figure 4.7D).   Second, 
mitochondria in SNORA21-/- K562 cells were smaller and more rounded than control cells 
(Figure 4.7E-F).   Of note, the mitochondrial morphology, but not loss of membrane 
integrity, has been reported in cells undergoing ferroptosis359.  
 
Loss of SNORA21 is associated with impaired mitochondrial function 
To test the hypothesis that loss of SNORA21 induces cell death via ferroptosis, we first 
measured lipid peroxidation, which is the classic feature of ferroptosis.   However, lipid 
peroxidation, as measured using fluorescent C11-BODIPY, was similar in SNORA21-/- 
K562 cells and control cells (Figure 4.8A-B).   Prior studies have established that 
ferroptosis is induced by treatment with erastin and inhibited by treatment with ferrostatin-
1359,360.   However, treatment with ferrostatin-1 did not reverse the impaired cellular 
proliferation of SNORA21-/- K562 cells (Figure 4.8C).   Moreover, SNORA21-/- K562 cells 
showed no increased sensitivity to erastin-induced cell death.   Based on these data, we 
conclude that loss of SNORA21 does not induce cell death through ferroptosis. 
The altered mitochondrial morphology prompted us to characterize 
mitochondrial function in SNORA21-/- K562 cells.   Mitochondria number, as measured 
using Mitotracker, was markedly reduced in SNORA21-/- K562 cells (Figure 4.8D-E).  
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Studies are underway to further assess mitochondrial function by measuring cellular ROS 



























There have been numerous studies characterizing the transcriptome and genome 
in AML.  However, the contribution of altered translation in AML pathogenesis has 
received little attention.   As outlined in the Introduction, there is convincing evidence that 
snoRNAs play a key role in the regulation of ribosome function and translation.   Our small 
RNA sequencing identified SNORA21 as a snoRNA that is differentially expressed in AML 
compared with normal CD34+ cells.   All of the genetic subtypes AML analyzed in this 
study, except APML showed reduced SNORA21 expression, with spliceosome gene-
mutated AML showing the largest difference (a nearly 3-fold decrease in median 
expression).   Moreover, we observed marked heterogeneity of snoRNA21 expression 
between AML cases with genetic subtypes. For example, in spliceosome gene-mutated 
AML, a 20-fold range in SNORA21 expression was observed.  Whether there is 
heterogeneity in SNORA21 expression within an AML sample is an open question.  
Unfortunately, current single cell RNA sequencing approaches to do not efficiently 
capture snoRNAs due to their small size and lack of a poly-adenylation tail.   
Prior studies in yeast have established that snR10, the yeast ortholog of 
SNORA21, is required for normal ribosome biogenesis, function, and translational control 
118,128,288.  SnR10-/- yeast have impaired cellular growth and reduced global protein 
translation.  The function of SNORA21 in mammalian cells is less well studied.  Qin et al., 
showed that enforced expression of SNORA21 in a gall bladder cancer cell line resulted 
in impaired growth both in vitro and in vivo248.  Here, we show that genetic loss of 
SNORA21 in K562 cells results in impaired ribosome function as evidenced by a loss of 
80S monosomes and polysomes and a global decrease in protein translation.   Studies 
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are underway to confirm that SNORA21-/- in K562 cells have reduced pseudouridylation 
at U4470 and U4401 in rRNA.   Yoon et al., reported that primary murine and human cells 
carrying loss-of-function mutations of DKC1, the major pseudouridine synthase in 
mammalian cells, have global reduction in pseudouridine125.   Moreover, they showed 
that DKC1-deficient cells had a specific defect in the translation of mRNA species carrying 
an IRES motif.   In contrast, in SNORA21-/- K562 cells, our ribosome sequencing results 
identified a limited number of genes with altered translational efficiency.   Moreover, most 
of these genes showed increased translational efficiency and there was no specific effect 
on IRES-containing transcripts.   Together, these data suggest that pseudouridylation at 
other rRNA sites is responsible for the selective defect in translation of IRES-containing 
transcripts.   
Similar to yeast, we show that loss of SNORA21 in K562 cells results in a marked 
decrease in cellular proliferation.   Surprisingly, the rate of cell division, as assessed by 
cell cycle status and EdU incorporation was normal, suggesting increased cell death.  
However, no increase in apoptosis was observed.   Thus, we conclude that loss of 
SNORA21 in K562 cells resulted in a non-apoptotic cell death.   We initially suspected 
that increased autophagy may have contributed to cell death.   However, electron 
microscopy  of SNORA21-/- K562 cells did not show the double-membrane phagosomes 
that are typical of autophagy.   Instead, electron microscopy revealed alterations in 
mitochondrial morphology and plasma membrane disruption (which is suggestive of 
necrosis).   The disruption of mitochondria was confirmed using Mitotracker, which 
showed that mitochondrial mass in SNORA21-/- K562 cells was significantly reduced.   Of 
note, prior studies have linked impaired ribosome biogenesis and endoplasmic reticulum 
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stress to altered mitochondrial function361.   Thus, our current working model is that 
decreased ribosome function in SNORA21-/- K562 cells results in impaired mitochondrial 
function, ultimately leading to cell death.  Studies are underway to further characterize 
mitochondrial function in SNORA21-/- K562 using a Seahorse XF Analyzer and by 
measuring mitochondrial or cellular reactive oxygen species.   A caveat of our current 
study is the use of K562 cells, which lack TP53 and contain other chromosomal 
abnormalities.   It will be important to confirm these findings using primary hematopoietic 
cells.   
In summary, we provide evidence suggesting that the decreased expression of 
SNORA21 in AML may contribute to the regulation of translation by modifying ribosome 
function.   Studies to correlate SNORA21 expression to global translation in primary 
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Summary and future directions 
Next-generation sequencing has dramatically advanced our ability to interrogate the 
transcriptome of normal and malignant cells.  However, initial studies focused on larger 
transcripts (>200 nucleotides) or miRNAs, resulting in a “sequencing gap” for small RNAs 
in the 25-200 nucleotide range.  In this research, we developed a next-generation 
sequencing approach that accurately quantify small non-coding RNAs, closing this 
sequencing gap.  We have used this assay to interrogate small non-coding RNA 
expression in normal hematopoiesis and acute myeloid leukemia.  We focused our study 
on snoRNAs, the most abundant type of small non-coding RNA.  Although snoRNAs have 
typically been considered to have housekeeping functions, we show that a subset of 
snoRNAs are regulated in a lineage- and development-specific fashion in hematopoiesis.  
Surprisingly, host gene expression and splicing correlated poorly with snoRNA 
expression suggesting that other mechanisms regulate the level of mature snoRNAs.  
One future direction would be to characterize these mechanisms.  For example, there is 
evidence snoRNAs are protected from exonuclease digestion by binding to the snoRNP 
proteins, such as NOP56/NOP58.  Studies to correlate snoRNP protein expression to the 
expression of specific snoRNAs may be informative.   
We show that a subset of snoRNAs are differentially expressed in AML compared 
to normal CD34+ cells.  The most striking example is the dysregulation of snoRNA 
expression in the imprinted DLK-DIO3 locus in APML.  Confirming prior reports, we show 
that expression of snoRNAs in this locus are increased up to 1000-fold in APML.  In 
contrast, expression of snoRNAs from the other major imprinted locus in humans, the 
SNURF-SNRPN locus, is reduced in APML.  This observation raises several important 
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unanswered questions.  First, what are the mechanisms resulting in increased DLK-DIO3 
snoRNA expression.  In contrast to a prior report, we have observed no change in 
methylation in the DLK-DIO3 locus nor is imprinting altered (data not shown).  Studies to 
characterize the chromatin organization of this locus in APML through Hi-C, or other 
chromosome conformation capture techniques may be informative.  A second question is 
to characterize the contribution of increased DLK-DIO3 snoRNA expression to APML 
pathogenesis or response to therapy.  DLK-DIO3 snoRNAs are considered orphan 
snoRNAs, with no known or convincing predicted target mRNAs.  Studies to assess the 
impact of DLK-DIO3 snoRNA expression of hematopoietic stem/progenitor cells may be 
difficult, since expression of multiple (>20) snoRNAs is increased in APML.  Thus, 
expressing a single DLK-DIO3 snoRNA may not be sufficient to induce changes in cell 
biology.  RNA immunoprecipitation approaches have been used to identify miRNA 
targets.  A similar approach could be used to pull down snoRNA/snRNP complexes to 
identify snoRNA targets.   
We also identified a limited number of differentially expressed snoRNAs in other 
genetic subtypes of AML.  The analysis of additional AML samples is needed to confirm 
these findings and identify candidate snoRNAs for biologic validation.  Of particular 
interest, are ongoing studies to assess the impact of altered RNA splicing in spliceosome-
gene mutated AML on snoRNA expression.  The focus of our analysis will be on host 
genes that contain snoRNAs in their introns.  The major focus of future studies would be 
to model the impact of snoRNA expression loss (or gain) on hematopoietic stem 
progenitor proliferation, differentiation, and ribosome function.  Another potential future 
direction would be to use our sequencing approach to interrogate the small RNA 
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transcriptome of other cancers.  Finally, it would worthwhile to modify single cell RNA 
sequencing approaches to interrogate snoRNAs and other small non-coding RNAs.  
Relatively modest changes to the library generation protocol that take advantage of the 
3’-hydroxyl group of miRNAs and snoRNAs may be sufficient to allow for their detection 
by single cell RNA sequencing.  
There is increasing evidence that regulation of translation plays an important role 
in the regulation of hematopoietic cell proliferation and differentiation.  Our data suggest 
that regulation of snoRNA expression may be one mechanism controlling translation.  In 
particular, our research suggests that SNORA21 may play an important role in regulating 
ribosome function.  SNORA21 expression was modestly but significantly reduced in most 
of the AML genetic subtypes that were analyzed.  Moreover, we observed marked 
variation in SNORA21 expression within AMLs of a given genetic subtype.  Our data show 
that the complete loss of SNORA21 in K562 cells results in reduced cell growth, impaired 
ribosome biogenesis, and overall reduced global translation.  This proof-of-principle 
experiment established the importance of SNORA21 in regulating ribosome function in 
human cells.  However, it is not clear whether the more modest changes in SNORA21 
expression seen in AML is sufficient to alter translation.  To address this concern, there 
are several experiments that could be done.  First, we could study ribosome function in 
cell models where SNORA21 expression is reduced, but not completely lost.  Second, we 
could analyze primary AML samples to determine whether protein translation rates 
correlate with SNORA21 expression.  The second experiment will be limited by the 
number of AML cells that are typically available for analysis.   
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Our studies show that loss of SNORA21 in K562 cells results in non-apoptotic cell 
death.  A major future direction would to better characterize the type of cell death and 
define the pathways leading to cell death.  As outline in Chapter 4, current evidence 
argues against autophagy or ferroptosis.  Rather, our data suggest that altered 
mitochondrial function may be responsible.  Ongoing studies to further assess 
mitochondrial function using the Seahorse CF flux analyzer and assays to measure 
mitochondrial potential and ROS may be informative.  Of note, K562 cells lack TP53 and 
ARF, key components of the ribosomal stress pathway.  Thus, it also will be important to 
assess the impact of the loss of SNORA21 in cells with intact TP53 and ARF.  One 
approach would be to use CRISPR-gene editing to delete SNORA21 from cord blood 
CD34 cells and assess the impact on cell proliferation and differentiation.   
                In summary, this research has provided new insight into the expression and 
function of snoRNAs in normal and malignant hematopoiesis.  In particular, this research 
supports the hypothesis that snoRNAs, by regulating ribosome function and protein 
translation, may contribute to the regulation of hematopoietic proliferation, survival, and 
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Figure 4.1. snoRNAs targeting the PTC domain of the ribosome have reduced expression in AML. A) SNORA21 
normalized expression across CD34 from healthy donors, AML samples with normal karyotype (NK), AML samples with 
mutations in splicing factors, AML samples with PML-RARa, core binding factor or MLL fusions. B) Overview of the 28 and 
5.8S ribosome structure with rRNA modifications. Critical PTC region is circled in blue. Image courtesy Wayne Decateur. 
Log transformed expression in healthy donor CD34 (blue circle), AML fusions (table 3.1) (red triangles) and samples with 
mutations in splicing factors (green square) of all snoRNAs that target PTC. C) Expression of C/D box snoRNA that target 
the PTC. D) Expression of H/ACA snoRNAs that target the PTC.  
 




Fig 4.2. Generation of SNORA21. A) Schematic representation of genome-browser view and SNORA21 genomic locus is 
shown. gRNAs as well as primers for validation are shown. B) Sanger sequencing analysis of the CRISPR/Cas9-target site 
shows the alignment of the wild-type (blue) and SNORA21-/- (red) sequences indicating the 126 bp SNORA21 deletion 
(dashed line). C) Box plots of normalized SNORA21 expression in WT and SNORA21-/- samples. Analyzed using Partek 
Flow. D) Relative expression of the candidate genes analyzed by RT-qPCR. Relative expression of host gene RPL23 in 
WT and SNORA21-/- samples analyzed by RT-qPCR gene expression. 
 





Figure 4.3. SNORA21 is required for ribosome biogenesis. A) Representative sucrose density gradient profiles of 
ribosomes from SNORA21-/- and WT K562 cell extracts showing the absorbance (A254 nm) of 40S, 60S, and 80S 
ribosomes. B) Summary data showing the 40S, 60S, 80S and polysome quantification. C) Representative FACS histograms 
of OP-Puro incorporation with control (grey), WT (blue), CHX treated (green) and SNORA 21-/- K562 cells (red). D) Mean 
intensity of OP-Puro fluorescence presented in control, CHX treated and SNORA 21-/- K562 cells.  
 




Figure 4.4. Translation efficiency. A) Plot show the frequency of log2 transformed translation efficiency (TE) ratio where 
TE is which is the ratio of the abundances of translated mRNA (RiboSeq-ribosome occupancy and available mRNA 
(RNASeq-transcript levels). B) Although most transcripts showed no differential regulation between the WT and SNORA21-
/- populations, several dysregulated genes were significantly (FDR ≤ 0.05) regulated at the level of mRNA abundance only 
(purple dots, RNASeq-only), ribosome occupancy only (red dots, RiboSeq-only), and at the level of both mRNA abundance 
and ribosome occupancy (green dots, RiboSeq+ RNASeq). Differences in translational efficiency were calculated in Ribodiff 
on transcripts with average RNA-seq DESeq2 normalized read counts ≥ 10.  
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Figure 4.5 Loss of SNORA21 leads to altered cell growth. Cells were plated in triplicate in 6-well plates (100,000 
cells/well) with growth medium. Cells were counted in triplicate at the indicated time points with a Bürker chamber cell 
chamber after 0.2% Trypan Blue staining to exclude apoptotic/necrotic cells. B) Real-time cell counting of cells labeled with 
NucLight Red. Cells were incubated at 37°C 5% CO2 in the IncuCyte live-cell imaging system as described in “Methods.” 
C) Cell cycle analysis of K562 cells. Effects of SNORA21 deletion on the cell cycle distribution in K562 cells were analyzed 
using flow cytometry analysis. Representative DNA histograms display cell cycle phase distribution of WT and SNORA 21-
/- K562 cells. D) Bar charts representing the percentage of various cell populations in WT and SNORA 21-/- K562 cells. E) 
Loss of SNORA21 has no significant effect on proliferation. Analysis of the cell proliferation rate with Click IT EdU cell 
proliferation assays (Thermo Fisher) shown in 2-hour representative plots from wildtype and SNORA21-/- K562 cell lines, 
respectively having incorporated EdU and labeled with azide. F) Summary statistics for 2 and 4-hour incubation with EdU. 
G) SNORA21 loss has no effect the extent of apoptosis in K562 cells. Intracellular caspase-3/7 activity was assessed 
by luminescence assay. Luminometer readings were taken 1 hour after adding reagents. Luminescence was proportional 
to caspase-3 activity. Background readings were determined from wells containing culture medium without K562 cells and 










Figure 4.6 Loss of SNORA21 impacts ribosome biogenesis A) KEGG pathway mapping analysis identified 8 pathways 
that were significantly enriched among the DEGs. B) Gene ontology enrichment analysis showing representative ontology 
categories. The enrichment p value is displayed on the side. The enrichment score is the negative natural log of the 
enrichment p-value derived from Fisher's Exact test. 
 




Figure 4.7. Transmission electron microscopy analysis of K562 cells. A) HBSS induced autophagy in K562 cells. 
Transmission electron microscopy (TEM) micrographs shows the ultrastructure of WT K562 cells incubated with HBSS for 
3 hours. B) Cells after 6-hour HBSS incubation. Numerous autophagic vacuoles were observed in the HBSS-treated cells. 
C) SNORA21-/- cells incubated in growth media. D) Plasma membrane integrity loss in SNORA21-/- cell undergoing necrosis. 
(black arrow). E) Wildtype K562 cell with mitochondria highlighted. Inset shows micrograph of normal mitochondria with 
typical tubular cristae, large matrix, outer membrane, the intermembrane space, and inner membrane. Mitochondria is of 
normal shape and size. F) Electron micrograph of SNORA21-/- K562 cells demonstrating the presence of numerous 
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mitochondrial aggregates containing various variable numbers of misshapen - smaller rounded and oval shaped - 
mitochondria (arrow). Clusters of many misshapen mitochondria were common within these aggregates (inset). TEM images 
were captured at magnifications of A. x8000, B. x4000, C. x4000, D. x4,000. E. ×3,000 and ×60,000 (E, inset), and F 














Figure 4.8 Loss of SNORA21 leads to a loss of mitochondrial mass. A) Representative plot derived from flow cytometry 
analysis of lipid peroxidation using C11-BODIPY (581/591) probes. B) Results from assessment of lipid peroxidation on 
three samples. C)  WT and SNORA21-/-  cells were plated in 96 well plates in the presence of either DMSO or 10 µM 
ferrostatin-1, and survival was quantified after 7 d by Incucyte. Ferrostatin with ferrostatin-1 did not reverse the impaired 
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cellular proliferation of SNORA21-/- K562 cells. D-E) The Mitotracker assay followed by flow cytometry revealed a shift of 
fluorescence intensity in SNORA21-/- K562 cells, indicating decreased amount of mitochondria.   
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